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Resumo  
  O desenvolvimento de Radiofármacos específicos capazes de detectar e/ou tratar 
neoplasias continua a ser uma das mais importantes áreas de investigação, uma vez que o 
cancro tem grandes taxas de incidência na população mundial. A utilização de péptidos 
biologicamente activos é uma estratégia para direccionar os radiofarmacos aos tumores 
de uma forma específica, já que os receptores que os reconhecem estão sobreexpressos 
numa grande variedade de tumores. 
A introdução dos precursores organometálicos fac-[M(H2O)3(CO)3]+ (M=Re, 99mTc) 
permitiu explorar novas metodologias na marcação de péptidos com radioisótopos de Tc 
ou Re, com base numa química bem definida e facilmente adaptavél a diferentes 
estratégias de bioconjugação. Apesar desta vantagem, o uso de complexos de tricarbonilo 
de Tc(I)/Re(I) na marcação de péptidos tem conduzido a radiopéptidos com uma 
farmacocinética pouco favorável. Mais do que uma limitação intrinseca da aproximação 
tricarbonilo, esta tendência reflecte a utilização de ligandos bifuncionais (LBF) que 
originam péptidos radiomarcados com caracter lipofílico, com uma excreção hepatobiliar 
indesejável. Assim, a concepção de novos LBF para marcação de péptidos com a unidade 
fac-[M(CO)3]+ ainda se reveste de grande importância de modo a aproveitar a elevada 
estabilidade in vitro/in vivo dos complexos tricarbonilo. 
Nesta tese, estudou-se a utilidade e influência de diferentes LBF tridentados na 
radiometalação de péptidos, com base na aproximação tricarbonilo. O péptido avaliado é 
um análogo de um Antagonista da Bombesina designado por AR. Este péptido é 
reconhecido pelos receptores do péptido libertador da Gastrina (GRP-r; Gastrin releasing 
peptide-receptor), sobreexpressos em vários cancros, nomeadamente no cancro da 
próstata.  
Neste contexto, o objetivo a longo prazo do trabalho descrito nesta tese foi 
contribuir para a concepção de novos radiofármacos específicos baseados em 
[99mTc(CO)3]+ para a visualização in vivo dos receptores da GRP, nomeadamente nas 
neoplasias da próstata. Para alcançar este objetivo, foram sintetizados três quelantes 
bifuncionais diferentes e caracterizados pelas técnicas usuais em química, incluindo ESI-
MS, RMN e HPLC, tendo sido posteriormente conjugados ao AR. Os ligandos bifuncionais 
estudados contêm pirazolilo (L1 e L2) e imidazolilo (L3) como grupos coordenantes e têm 
o mesmo número e tipo de átomos coordenantes (N,N,N). Esperava-se que conduzissem a 
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complexos estáveis de Re(I)/Tc(I), cuja farmacocinética fosse facilmente optimizada por 
introdução de grupos hidrofílicos nos anéis de pirazolilo e imidazolilo.  
Os dois LBF derivados do pirazolilo que foram estudados contêm espaçadores 
diferentes entre o grupo carboxílico terminal a usar para ligação ao péptido e a amina 
central do ligando: L1 contém um braço do tipo propilo e o L2 um braço metilo. Desta 
forma, esperava-se avaliar a influência da distância do péptido biologicamente activo ao 
centro metálico no perfil biocinético dos radioconjugados resultantes. O L1 é um quelante 
do tipo pirazolilo que já se encontra bastante estudado pelo Grupo de Ciências 
Radiofarmacêuticas (C2TN-IST) e tem excelentes propriedades de coordenação face ao 
centro metálico tricarbonilo, bem como fácil conjugação a biomoléculas, nomeadamente a 
péptidos.  
Foi avaliada a capacidade de coordenação de um  novo ligando (L5), contendo um 
grupo coordenante do tipo imidazolilo, face à unidade  [M(CO)3]+(M = Re, 99mTc). No caso 
do 99mTc, este estudo conduziu a um complexo hidrofílico que foi obtido com rendimento e 
pureza radioquímica elevados. Este complexo apresenta ainda uma elevada estabilidade in 
vitro e in vivo e estudos de biodistribuição em ratinho mostraram que tem um perfil 
biocinético favorável. Assim, concluimos que este ligando tem características favoráveis 
para conjugação com péptidos biologicamente activos. 
Os análogos peptidicos sintetizados basearam-se na seguinte sequência: DPhe1-
Gln2-Trp3-Ala4-Val5-Gly6-His7-Sta8-Leu9-NH2 (AR), a qual foi acoplada a um espaçador de 
polietilinoglicol (PEG) por forma a aumentar a distância entre o centro metálico e a BM e 
conferir um carácter mais hidrofílico aos conjugados. Para a síntese destes péptidos foi 
utilizada a estratégia de sintese em fase sólida (resina) e aminoácidos protegidos com o 
grupo protector Fmoc. Após cada síntese e/ou conjugação a derivados dos ligandos L1-L3, 
os péptidos e conjugados peptídicos (AR, ARPEG2, L4, L6 e L7) foram purificados e 
caracterizados por ESI-MS e HPLC.  
No caso do conjugado peptídico L4, resultante da conjugação de ARPEG2 a um 
derivado de L1,  iniciou-se o estudo da sua radiomarcação com 99mTc. São necessários mais 
estudos para melhorar as condições de marcação e continuar com os necessários estudos 
de captação celular em células tumorais de cancro da próstata e de biodistribuição e 
farmacocinética em ratinhos com tumores induzidos. Esses estudos deverão ser alargados 
aos restantes bioconjugados de modo a investigar quais são os mais promissores para a 
concepção de novos radiofármacos para detecção de cancro da próstata. 
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Abstract  
The development of radiopharmaceuticals for imaging/therapy of cancer remains 
an important issue. Biologically active peptides are used as specific carriers for the 
targeting of tumors, as many peptide receptors are overexpressed in  tumors.  
The organometallic precursors fac-[M(H2O)3(CO)3]+ (M=Re, 99mTc) allow the 
labeling of peptides based on a well-defined and easily adaptable chemistry. However, the 
resulting complexes are often lipophilic and show unfavorable pharmacokinetics. 
Improving this issue is still crucial, which requires the design of new BFC’s (bifunctional 
chelator) for coordination of fac-[M(CO)3]+ and aiming to obtain radiopeptides with  more 
favorable in vivo profile.   
In this context, the goal of this thesis was to contribute for the development of 
radiopharmaceuticals based on [99mTc(CO)3]+ for in vivo imaging of tumors overexpressing 
the Gastrin Releasing Peptide-receptor (GRP-r,), particularly prostate cancer. To 
accomplish this goal, three different BFC’s were synthesized, characterized and conjugated 
to a bombesin antagonist peptide, with known ability to target GRP-r.  
The investigated BFC's contain pyrazolyl (L1, L2) and imidazolyl (L3) coordinating 
groups and can lead to hydrophilic complexes of Re(I)/Tc(I).  Pyrazolyl-diamine chelators 
like L1 and L2 are known to have excellent properties to stabilize the [M(CO)3]+ core.On 
contrary, imidazolyl-diamine chelators like L3 were not explored so far. Therefore, a 
model imidazolyl-diamine ligand, L5, was synthesized its coordination capacity towards 
the [99mTc(CO)3]+ evaluated. L5  forms a hydrophilic complex, in high radiochemical yield 
and purity, which presents  high stability in vitro/in vivo and a favorable biokinetic profile.  
The synthesized peptide analogs were based on the following sequence: DPhe1-
Gln2-Trp3-Ala4-Val5-Gly6-His7-Sta8-Leu9-NH2 (AR). A spacer of polyethyleglycol (PEG) was 
conjugated to AR, to impart a more hydrophilic character. For the synthesis of peptides, a 
solid phase (resin) and Fmoc strategy were used. These studies led to the synthesis of 
several peptide conjugates (AR, ARPEG2 and L4). It was inititated the study of the 
radiolabeling of L4 with[99mTc(CO)3]+. This preliminary results indicated that more studies 
are needed to improve the labeling and proceed with the evaluation of cellular uptake and 
biodistribution/pharmacokinetics in mice with induced prostate tumors. 
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Scope and Aim 
Cancer remains one of the most devastating diseases with more than 10 million 
new cases each year world-wide, which is estimated to increase to 20% by 2020. However, 
due to a better understanding of cancer, and improved diagnostics equipment and 
treatment strategies, the mortality is decreasing.(1)  
Prostate cancer (PC) has been the most frequently diagnosed noncutaneous cancer 
and is the second cause of cancer-related mortality after lung and bronchus cancers in 
men. (2,3) An optimal PC treatment is guided by a clinically staging of the cancer and 
selecting treatment options based on the stage. The treatment options for men with 
prostate cancer may include an expectant management (watchful waiting) or an active 
surveillance, that included surgery; radiation therapy; cryosurgery (cryotherapy); 
hormone therapy; chemotherapy; vaccine treatment and bone directed treatment. These 
treatments are generally used one at a time, although in some cases, they may be 
combined. (1)  
Prostate cancer continues to be the second leading cause of cancer-related deaths 
for men in developed countries. Although the 5-year disease-specific survival rate of 
localized disease treated by surgery or radiotherapy is more than 90%. The effectiveness 
of systemic therapy for advanced prostate cancer is limited. Currently, depleting or 
blocking the action of androgens is the standard of care for men with advanced prostate 
cancer, but the response to treatment is not durable and with time prostate-specific 
antigen concentrations increase, indicating reactivated androgen-receptor signaling. (2) 
Over the last years an emerging area in nuclear oncology deals with the evaluation 
of radiolabeled bioactive peptides for the diagnostic and therapy of tumors, due to 
overexpression of many peptide receptors in human tumors. Comparatively to other 
biomolecules, small peptides have many advantages. Namely, they can be easily 
synthesized and manipulated molecularly to optimize their in vivo half-life, receptor 
binding affinity and subsequently, pharmacokinetics. Peptide-based radiopharmaceuticals 
for therapeutic applications offer the ability to exploit the radioactive chelate as a 
radiocytotoxic unit and the bioactive molecule as a vector to localize the tumor.  
Bombesin-like peptides such as gastrin-releasing peptide (GRP) have been shown 
to play a role in cancer promoting growth factors that stimulate tumor growth through 
specific receptors. The GRP receptor shows high over-expression in invasive prostatic 
neoplasias and also, although in less cases,  in  bone metastases of androgen-independent 
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prostate cancers. This represents the potential clinical basis for GRP receptor imaging of 
prostate cancer with radioactive compounds for early tumor diagnosis, followed by 
radiotherapy with radiolabeled bombesin  analogues. 
Despite the remarkable advances, the design of specific probes for targeted 
imaging or therapy still remains a great challenge and a demanding task within the field of 
radiopharmaceutical sciences. This is a multidisciplinary research area, which profits from 
the input of chemists, radiochemists, radiopharmacists and clinicians. Due to its chemical 
and nuclear properties, associated with the low cost and easy availability, 99mTc is among 
the most attractive radionuclides for SPECT imaging. In addition, rhenium, the congener 
2nd row d-transition element from the 7th group, forms isostructural complexes with Tc 
and displays two radioisotopes (186Re and 188Re) suitable for targeted antitumor therapy.  
Within this framework, the long term goal of the work described in this thesis was 
to contribute for the design of new specific radiopharmaceuticals based on the 99mTc(CO)3 
core for in vivo visualization of GRP receptors overexpressed in prostatic cancer. To 
accomplish this goal, three different bifunctional chelators (BFC’s) were synthesized and 
conjugated to a bombesin analog peptide. This peptide was chosen because it was already 
established its usefulness as a targeting vector for GRP receptors. It was intended to 
radiolabel the different bioconjugates with 99mTc, to evaluate the in vitro stability of the 
resulting complexes, as well as its in vivo profile in mice, to have an insight on their 
relevance in the design of specific radiopharmaceuticals for prostate cancer imaging. 
Finally, the most promising radiopeptides would be evaluated using imaging and 
biodistributions studies in mice bearing prostatic tumors. In summary, this work 
comprised the synthesis and characterization of BFC’s; synthesis and characterization of 
the peptide analogues; conjugation of peptide analogues to the BFC’s (figure A.1); 
Synthesis of organometallic complexes of 99mTc and natRe, and finally  in vitro and in vivo 
studies for some of the 99mTc complexes. 
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Figure A.1 - Representation of peptide conjugates studied in this Thesis. 
This thesis is organized in five chapters. Chapter 1 comprises a general 
introduction on nuclear imaging in oncology and radiopharmaceuticals. It covers also  
peptide related matters, such as the relevance of Gastrin Releasing Peptide-receptors 
(GRP-r) as a target for tumor imaging and therapy, and the use of radiolabeled Bombesin 
(BN) analogues for in vivo imaging of GRP-r. Chapter 2 is dedicated to the description of 
all materials and methods used, namely the synthetic procedures. 
The 3rd chapter reports the results and discussions, and is divided into the 
synthesis of bifunctional chelators (BFC’s), peptide synthesis and conjugation, 
radiolabeling studies and biodistribution evaluation.  
Concluding remarks are presented in chapter 4, where is also scrutinized the 
options for the future work. 
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1.1  NUCLEAR  MEDICINE AND RADIOPHARMACEUTICALS 
1.1.1  General Considerations 
 
Nuclear medicine is a medical speciality that uses radiopharmaceuticals for 
diagnosis and/or therapy of several diseases. Radiopharmaceuticals are drugs with no 
pharmacological effect that contains in its composition a radionuclide. A 
radiopharmaceutical can be a small organic (e.g. 18F-FDG), inorganic (e.g. Na131I and 
Na18F), or organometallic compound with defined composition, or can also be a small 
peptide, inhibitors or substrates of enzymes or large molecules such as antibody 
fragments, among others. (3–5) 
1.1.2. Radionuclides 
A nuclide is an atomic nucleus identified by a unique combination of a given 
number of protons and neutrons and the energy state of its nucleus. A nuclide can be 
specified by the notation: A
Z
X N ; where X is the chemical element symbol, Z is the atomic 
number (number of protons in the nucleus), N is the neutron number (number of neutrons 
in the nucleus), A is the mass number (A=N+Z, total number of nucleons in the nucleus). A 
radionuclide is an unstable form of a nuclide, due the unsuitable composition of the 
nucleus. Radionuclides disintegrate emitting gamma ray(γ) and/or particles or 
Auger electrons. They may occur naturally, but most of them are artificially produced in 
cyclotrons or reactors. It is also possible to have indirect production routes like 
radionuclide generators. In this case a radionuclide (parent), produced in a reactor or 
cyclotron, is immobilized in a chromatographic column, allowing the elution of another 
radionuclide (daughter) with shorter half-life. The advantage of this process is to deliver 
very short-lived radionuclides (daughter) to hospitals or medical institutions that don’t 
have cyclotron or reactor facilities.  (6–8)  
1.1.3. Diagnosis Vs. Therapy in Nuclear Medicine 
Depending on the medical application, diagnosis or therapy, different physical 
properties are required for the radionuclide. Among these properties, the type and energy 
of the emitted radiation as well as the half‐life of the radionuclide (time necessary for half 
of the original atoms of the radionuclide to decay - t1/2) of the nuclide are the most 
important for selection of a suitable radionuclide to the desired medical application. A 
radiopharmaceutical for diagnosis contains a positron- (β+) or gamma- (γ) emitting 
radionuclide of sufficiently high energy (>50 keV) in their composition, whereas 
therapeutic radiopharmaceuticals have in their composition a radionuclide that emits 
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ionizing radiation with a high linear energy transfer (LET), to destroy selectively cells or 
tissues. The most used radionuclides for therapeutic purposes are β-, but intense research 
involving α and Auger electron emitters is also underway, like the Phase III Study of 
Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate 
Cancer With Skeletal Metastases (ALSYMPCA). (9) 
1.1.4. Nuclear Imaging  
Medicinal imaging is a key tool for improving the diagnosis of a large variety of 
diseases. Nowadays, the imaging techniques can be included into two large non-invasive 
categories: Structural and functional imaging techniques. X-ray, CT (Computed 
Tomography) and MRI (Magnetic Ressonance Imaging) are the three most important 
techniques that can primarily provide structural and anatomical imaging such as tumor 
location, size, morphology, and structural changes to adjacent tissues. (10–12) 
Functional imaging, rather than anatomical, aims at the visualization and 
characterization of biochemical pathways, molecular interactions, drug pharmacokinetic 
and pharmacodynamics. Positron Emission Tomography (PET) and Single Photon 
Emission Computed Tomography (SPECT) are currently accepted as the most important 
functional imaging techniques, used in nuclear medicine. (13,14)  
Examples of typical instruments available for small-animal molecular imaging are 
shown in Figure 1.2 and Table 1.1; they summarize the most relevant characteristics of 
imaging modalities mentioned above, including the major strengths and weaknesses. (13) 
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Figure 1.2 - Multiple imaging modalities are available for small-animal molecular imaging. There are views of 
typical instruments available, and illustrative examples of the variety of images that can be obtained with 
these modalities.(A) microPET whole-body coronal image of a rat injected with 18F-FDG; (B) microCT coronal 
image of a mouse abdomen after injection of intravenous iodinated contrast medium. (C) microSPECT coronal 
image of a mouse abdomen and pelvic regions after injection of 99mTc methylene diphosphonate, (D) Optical 
reflectance fluorescence image of a mouse (E) microMRI coronal T2-weighted image of a mouse brain. (F) 
Optical bioluminescence image of a mouse. (*adapted from(13)). 
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Table 1.1 - Relevant characteristics of the imaging modalities used in clinical set. 
 
Techniqu
e 
Spacial 
resolution 
Amount of 
molecular 
probe 
used 
Main use Advantages Disadvantages 
S
tr
u
ct
u
ra
l 
im
a
g
in
g
 MRI 25-100 m mg-g 
Morphological
/ 
Metabolic 
Higher spatial resolution, 
combines morphological and 
functional imaging 
Low sensitivity, 
amount of probe 
CT 50-200m 
Not 
applicable 
Morphological 
Bone and tumor imaging, 
anatomical imaging 
Limited soft tissue 
resolution 
US 
(ultrasons) 50-500 m mg-g Real time imaging, low cost 
Limited spatial 
resolution 
F
u
n
ct
io
n
a
l 
Im
a
g
in
g
 SPECT 1-2 mm 
ng Metabolic 
Highest sensitivity, quick, easy, 
low cost, relatively high 
throughput 
Low spatial 
resolution 
PET 1-2 mm 
High sensitivity, isotopes can 
substitute naturally occurring 
atoms 
Cyclotron or 
generator needed 
 
 From the nuclear imaging modalities, SPECT requires a radiopharmaceutical 
containing a radionuclide that emits gamma (γ radiation with energies between 80 and 
300 KeV and a gamma camera for patient imaging). PET requires a radiopharmaceutical 
labeled with a positron-emitting radionuclide (+) and a PET camera. (15)  
SPECT Imaging - The gamma rays are 
emitted by the radionuclide present in the 
injected radiopharmaceutical. These rays are 
detected by a gamma camera and an image of 
localized radioactivity is produced. In SPECT, the 
gamma camera rotates around the patient's body 
and the image is reconstructed to produce image 
slices.   
 
PET Imaging - The nucleus of the radionuclide decays by the 
emission of a positron (Positive electron) which will then 
combine with an electron from the surroundings tissues and 
annihilate to produce two characteristic γ-rays of energy 
equivalent to the rest mass energy of an electron (511keV). 
These are emitted at approximately 180º degrees away from 
each other. The PET scanner, used to detect the two photons, 
consists of a ring of scintillation detectors of which 
opposing detectors are in coincidence so that the 
 
Figure 1.3 – SPECT device from Philips. 
Figure 1.4– PET principle of 
detection. (108) 
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radionuclide can be determined to be in the region between the detector pair. 
Reconstruction of events between these multiple detector pair leads to a functional image 
of the brain. 
Although SPECT imaging has lower sensitivity in the detector and less quantitative 
accuracy than PET, it has broader clinical applications. In fact, the radioisotopes used in 
SPECT have longer half-life (t1/2) and therefore can be produced away from the site of 
administration and transported whenever required.(16) Moreover, the detection period 
can be widened, allowing the observation of biological processes in vivo over several hours 
or days after the administration of the radioactive probe.(17) 
The γ-emitting radionuclides with the most suited characteristics for SPECT 
imaging are 99mTc (t1/2 = 6.02 h, Eγ(max) = 140 keV), 123I (t1/2 = 13.20 h, Eγ(max) = 159 
keV), 67Ga (t1/2 = 78.26 h, Eγ(max) = 296 keV), 201Tl (t1/2 = 72 h, Eγ(max) = 167 keV) and 
111In (t1/2 = 67.9 h, Eγ(max) = 245 keV).  
The β+-emitting radioisotopes used in PET imaging are in general short-lived 
nonmetallic isotopes, such as 18F (t1/2 = 109.8 min, Eβ+ (max) = 202 keV), 11C (t1/2 = 20.4 
min, Eβ+ (max) = 326 keV), 15O (t1/2 = 2.03 min, Eβ+ (max) = 650 keV), and 13N (t1/2 = 9.98 
min, Eβ+ (max) = 432 keV). [18F]-2-fluoro-2-deoxy-D-glucose (18F-FDG) is the most widely 
used positron-emitting radiopharmaceutical for PET imaging, making 18F the most used 
radionuclide in this nuclear imaging technique. 18F-FDG has also shown clinical usefulness 
in cardiology and neurology, but it is used mainly in oncology, in the diagnosis, staging and 
post-therapy evaluation. (18,19)  
Most PET radionuclides have the disadvantage of requiring costly technology, namely 
cyclotrons for their production and sophisticated automated methods for the 
radiosynthesis of the radiopharmaceuticals. Owing to the short half-life of most β+-
emitting radioisotopes, the production and synthesis must occur close to the 
administration site. A few β+-emitting radiometals such as 64Cu (t1/2 = 12.7 h, Eβ+(max) = 
660 keV) and 68Ga (t1/2 = 1.1 h, Eβ+(max) = 1899 keV) are also of great interest in 
developing new PET radiopharmaceuticals. In particular,  68Ga is emerging as a PET 
radionuclide with clinical relevance, due not only to its physical and chemical properties, 
but mostly to  its availability from a long-lived 68Ge/68Ga generator system. (3,5,7,20–22) 
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1.1.5. Nuclear Therapy  
As mentioned before, radiopharmaceuticals for systemic radiotherapy have in 
their composition a radionuclide that emits ionizing radiation with a high LET to destroy 
selectively cells or tissues ( β- emitters, α- and Auger electron emitters). (7) These particles 
have different ranges in the tissues and can be described by the amount of transferred 
kinetic energy as a function of distance. 
The selection of a radionuclide for therapy depends not only on the type, energy, 
half-life and range of emitted particles, but also on the size of the tumor or tissue to 
irradiate and treat. Since the penetration depth range of β- particles in biological tissues is 
relatively long (0.1 – 10 mm), radiopharmaceuticals containing β--emitting radionuclides 
can be used for the treatment of large solid tumors. (9,23)  
Among β--emitting radionuclides with potential application, 131I (t1/2 = 8.0 d, Eβ-
(max) = 0.81 MeV, Eγ(max) = 0.364 MeV), 90Y (t1/2 = 2.7 d, Eβ- (max) = 2.27 MeV), 186Re (t1/2 
= 3.8 d, Eβ-(max) = 1.07 MeV, Eγ(max) = 0.137 MeV), and, more recently, 188Re (t1/2 = 0.7 d, 
Eβ- (max) = 2.10 MeV, Eγ(max) = 0.155 MeV), are used in the clinical onset for the 
treatment of different tumor types. Moreover, the radiolanthanides 153Sm (t1/2 = 1.9 d, Eβ- 
(max) = 0.8 MeV, Eγ(max) = 0.103 MeV), 166Ho (t1/2 = 1.1 d Eβ- (max) = 1.86 MeV, Eγ(max) 
= 0.081 MeV)  and 177Lu (t1/2 = 6.7 d, Eβ- (max) = 0.497 MeV, Eγ(max) = 0.208 MeV)  have 
been fully explored both at the preclinical and clinical levels as bone palliative agents 
(153Sm, 166Ho) and for peptide receptor radionuclide therapy in the case of 177Lu-labeled 
somatostatin analogs. (23–27) 
The α particles are heavy and charged helium nuclei with high LET. These 
particles “travel” only short distances and cause the most ionizing damage over a small 
distance (30 – 80 μm). Hence, α-emitting radionuclides are appropriate for the treatment 
of small tumors and/or metastasis. (9) Most of the α-emitters have a half-life that is too 
long to be compatible with in vivo applications. As a result, only a few of these 
radioisotopes have received serious attention for radiotherapeutic applications, namely, 
211At (t1/2 = 7.2 h, Eα(avg) = 6.8 MeV), 212Bi (t1/2 = 1 h, Eα(avg) = 7.8 MeV) and 223Ra (t1/2 = 11.4 d, 
Eα(avg) = 5.65 MeV). (23,24,28,29) It is worth mentioning that 223RaCl2 (Alpharadin®) was 
explored in the treatment of skeletal metastases and due to the promising results obtained 
this compound is currently under clinical evaluation for the treatment of bone metastases 
resulting from prostate cancer.  
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The Auger electrons are less energetic particles with a very short range of 
penetration (< 1 μm), having a LET similar to that of α particles, which makes them 
potentially interesting for therapy. Unlike α and β- particles, treatment based on Auger 
electron-emitters requires the targeting of individual cells, specifically the DNA in the 
nucleus. Despite the multiple obstacles that have to be overpass, Auger electron therapy 
approaches remain very appealing. Among the available Auger electrons-emitting 
radionuclides, 125I (t1/2 = 57 d, 24 electrons/decay), 111In (t1/2 = 67 h, 14 electrons/decay), 
67Ga (t1/2 = 78 h, 4 electrons/decay) and 99mTc (t1/2 = 6.02 h, 4 electrons s/decay) are the 
most interesting for potential clinical applications. (9,24,30–32) 
Perfusion and Specific Radiopharmaceuticals 
The radiopharmaceuticals can be classified according to their biodistributions 
profile as perfusion or first generation radiopharmaceutical and specific or second 
generation radiopharmaceutical. Most of the radiopharmaceuticals in clinical use are 
perfusion agents, but nowadays most of the research efforts are directed to specific 
radiopharmaceuticals for diagnostic and/or therapy. The biodistribution of perfusion 
agents depends mainly on their lipophilicity, size and charge. These agents are 
transported in the blood and delivered to the target organ in the proportion of the blood 
flow. A wide variety of compounds were successfully developed for imaging organs, such 
as liver, kidney, heart or brain, giving information on a pathologic condition. (6,33,34) 
In the last decade, due to the advances in molecular biology and the consequent 
identification and comprehension of molecular mechanisms that are the base of several 
diseases, the most recent radiopharmaceuticals in the market are specific 
radiopharmaceuticals. The targeting capability of these compounds depends on a 
biologically active biomolecule (BM), which can be a small organic BM, a small peptide, an 
antibody, a nanobody, sugars, inhibitors or substrates of enzymes, nucleotides or 
oligonucleotides. The capacity of the BM to recognize a certain molecular target (receptor, 
antigen, enzyme, DNA, mRNA, etc) will determine the radiopharmaceutical uptake in the 
target organ or tissue.  
 Since the end of 1980’s, an intensive research for developing specific 
radiopharmaceuticals is being carried out, but only some cases were successful in getting 
to clinical use. (4,6) In fact, this is a challenging task, since it is necessary to conjugate the 
radionuclide to a biomolecule without interfering with its biological properties. For the 
design of specific radiopharmaceuticals there are three general strategies: the integrated, 
the hybrid and the bifuncional approach (Figure 1.5). (6,23,34–36) 
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Figure 1.5– Representation of the integrated approach. 
The integrated approach involves the substitution of a part of a biologically active 
molecule by a metal unit. This replacement must minimize changes in the structure, 
molecular size and conformation. Figure 1.5 presents the basis of the integrated approach 
and figure 1.6 shows examples of this approach. So far, integrated approach did not 
provide good results, as the resulting molecules presented low specificity and biological 
affinity for the receptors.(36,37)  
 
Figure 1.6 – Exemples of the Integrated approach. Rhenium complexes which mimic the structure of 
dihydrotestoterone, progesterone and estradiol. (36) 
In the hybrid approach, the metal is stabilized by functional groups naturally 
occurring or synthetically introduced in the BM. These groups are usually tripeptides, such 
as GLY-GLY-GLY, CYs- GLY-GLY or CLYs-GLY-CYs. The small peptide sequence can be part 
of a linear or cyclic polypeptide. In some cases, the coordination of the radiometal to such 
amino acids can promote the cyclization of the polypeptide, improving the affinity for the 
receptors and increasing the in vivo stability. An example of such approach is the 99mTc(V)-
Depreotide (NeoTect®) (Figure 1.7) a radiopharmaceutical for imaging of somatostatin 
receptors pulmonary masses, in clinical use. (4,6)  
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Figure 1.7 – Molecular configuration of NeoTect®. (38) 
 The bifunctional approach (Figure 1.8) has been the most exploited for the 
development of specific radiopharmaceuticals.  
 
Figure 1.8 – Representation of the Bifuntional Approach (BFA); BM= biomolecule 
This approach uses a bifunctional chelator (BFC)  that strongly coordinates the 
metal ion, through appropriate coordinating groups, and is covalently attached to the 
biomolecule, which much interact specifically with the desired target. The nature of the 
BFC depends on the metal and its oxidation state. A spacer/linker between the metal and 
the biomolecule may exist, to modulate either the pharmacokinetics of the compound 
and/or its biological activity. This approach has been successfully used for the 
development of some radiopharmaceuticals, as it is for example the case of Octreoscan®, a 
radiopharmaceutical based on 111In in clinical use for the imaging of neuroendocrine 
tumors. (39) 
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Figure 1.9 – 111In-OctreoScan. In this case, the BFC used is 2-[Bis[2-
[bis(carboxymethyl)amino]ethyl]amino]acetic acid (DTPA). 
 
1.2. TECHNETIUM AND RHENIUM COORDINATION CHEMISTRY RELEVANT FOR NUCLEAR 
MEDICINE 
Technetium was discovered in 1937 by Perrier and Segrè in a sample of 
molybdenium, which was irradiated by deuterons. The new element received its name 
from the Greek word technetos, meaning artificial, because technetium was the first 
element previously unknown on earth to be made artificially. In 1939 Seaborg and Segrè 
observed that molybdenum-98 irradiated with slow neutrons gave rise to 99Tc through 
decay of the metastable isomer, 99mTc.  Eventually 21 isotopes of technetium were 
discovered ranging from 90Tc to 110Tc, with technetium-110 having the shortest half life 
(0.86 Sec) and 97Tc the longest (2.6 x 106 y). All technetium isotopes are radioactive. In the 
1950s, a purification work on the tellurium-132 / iodine-132 generator at Brookhaven 
National Laboratory (BNL) turned up a contaminant which was proved to be technetium. 
The technetium contaminant was due to the presence of 99Mo in the chemical separation, 
which was also present, because it had followed tellurium in the chemical separation 
process. This discovery eventually led to the production of the 99Mo/99mTc generator in 
1957 at BNL. Final improvements were made by Powell Richards. (40) 
Rhenium, first detected by Noddack, Tacke and Berg in 1925 in the X-ray spectra of 
certain mineral concentrate, was the last of the stable elements to be discovered. Rhenium 
occurs naturally as a mixture of two isotopes: 185Re(37.4%) and 187Re(62.6%) and has two 
radioactive isotopes with an interest in nuclear medicine: 186Re and 188Re, two β- emitters 
that can be used in therapy. Due to its availability from the generator (188W/188Re) and 
favorable nuclear properties, 188Re is being intensively studied for the design of 
therapeutics radiopharmaceuticals.  
Technetium (Tc) and rhenium (Re) are group 7 transition metals, belonging 
respectively to the 2nd and 3rd transition series, with atomic numbers 43 and 75 and 
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electronic configurations [Kr]4d55s2 and [Xe]4f145d56s2, respectively. Tc complexes can 
have the metal in the oxidation states -I (d8) to +VII (d0), whereas for Re complexes the 
metal presents oxidation states -III (d10) to +VII (d0). These metals present very similar 
atomic radius (Tc, 1.36 Å; Re, 1.37 Å), forming structurally analog complexes. For that 
reason, the characterization of 99mTc complexes (obtained at very low concentration, 10-10-
10-7M) is usually supported by the synthesis of analogs rhenium complexes. However, 
there are differences between both metals that must be taken into consideration in the 
preparation of Tc and Re complexes. The most striking difference is related to the higher 
kinetic inertness and easier oxidation associated to Re complexes. (7,41) 
1.2.1. Radiochemistry of Technetium 
The growth and wide application of diagnostic nuclear medicine have been mainly 
driven by the coordination chemistry and unique features of technetium. Among the 21 
known artificial isotopes, 99mTc is the most useful radioisotope in nuclear medicine. The 
importance of 99mTc in nuclear medicine is related to its almost ideal characteristics: (4,34) 
- Half‐life of 6.02h is optimal for diagnostic, which is long enough to examine 
metabolic processes and yet short enough to minimize the radiation dose to the 
patient; 
- γ-emitter (140 keV) with energy sufficiently high to penetrate easily the human 
body and to be detected externally by a gamma camera, and sufficiently low to 
minimize the dose to the patient; 
- Available at reduced prices from a commercial 99Mo/99mTc generator, being one of 
the greatest advantages of this radionuclide; 
- Diverse coordination chemistry, which enables the preparation of a wide variety of 
complexes with different physicochemical and biological properties. 
 
The prominence achieved by 99mTc as a useful radioisotope in nuclear medicine is 
directly related to the design and development of a 99Mo/99mTc generator in the late 
1950’s. (42–44)  
Molybdenium-99 (99Mo), with a half-life of 66h, undergoes a radioactive decay, 
emitting β‐ particles, in which 87% of the 99Mo atoms is converted directly into the 
metastable state 99mTc, whereas 13% pass directly to the fundamental state 99Tc (Fig  1.10)  
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Figure 1.10 – Left: illustration of the contents of a 99Mo/99mTc generator;Right: Decay scheme of 99Mo. There is 
a 2-keV isomeric transition from the 142-keV level to the 140-keV level, which occurs by internal conversion. 
Approximately 87% of the total 99Mo ultimately decays to 99mTc and the remaining 13% decays to 99Tc. (7) 
1.2.2. Coordination chemistry of 99mTc 
The design of 99mTc-radiopharmaceuticals depends on the understanding of the 
coordination chemistry of 99mTc. Factors such as stable oxidation states and core 
structures are crucial in the design of effective target-specific 99mTc-radiopharmaceuticals. 
The [99mTcO4]- anion, also known by pertechnetate, presents the metal in the 
highest oxidation state possible (+VII) being an easily accessible precursor in the synthesis 
of all 99mTc-based complexes for imaging application. It is the most stable form of 
technetium in aqueous solution, however, does not bind directly to any ligand and thus, 
for the synthesis of a 99mTc-radiopharmaceutical, reduction of 99mTc(VII) to a lower 
oxidation state in the presence of a suitable ligand is a prerequisite. Several reducing 
agents such as tin salts (SnCl2, tin citrate, tin tartrate) or sodium borohydride, as well as 
different reaction conditions (pH, temperature, concentration) are used to reduce [TcO4]- 
in aqueous solution, yielding a technetium core in a lower oxidation state that is stabilized 
by a suitable chelator. (5,9)  When reduced in the presence of a ligand, the [99mTcO4]- 
usually does not release all the oxygen atoms, leading to complexes with different 99mTc 
cores.(45) 
99mTc is usually used in the oxidation state +V as [99mTcO]3+ or [99mTcO2]+ cores.(6) 
The coordination chemistry of the [99mTcO]3+ core has been explored for a long time but, 
more recently, a lot of attention has been focused on the use of organometallic cores for 
the radiolabelling of BMs. In fact, the 99mTc(I)- and Re(I)-tricarbonyl core [M(H2O)3(CO)3]+ 
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(M = 99mTc/188Re), or simply the [M(CO)3]+ core, has been adopted as an alternative 
strategy to the 99mTc(V) complexes for the synthesis of 99mTc-radiopharmaceuticals. 
Nowadays, the research is focused on the synthesis of new chelators that can coordinate 
strongly to the [M(CO)3]+ core. (6,20,33,45) 
1.2.2.1. The [M(CO)3]+ core (M = 99mTc, Re) 
The [M(CO)3]+ core (M = 99mTc, Re) has been adopted as an alternative strategy to 
the 99mTc(V) complexes for the synthesis of 99mTc-radiopharmaceuticals. Nowadays, the 
research is focused on the synthesis of new chelators that can coordinate strongly to the 
[M(CO)3]+ core. (6,20,33,45) 
Alberto et al. were the first to report the one-step synthesis of an organometallic 
Tc(I) aqua-ion, [99mTc(H2O)3(CO)3]+, useful as a precursor for the radiolabelling of BMs for 
diagnostic purposes. The Tc(I)-tricarbonyl precursor was synthesized by direct reduction 
of the [99mTcO4]- from the oxidation state +VII to +I, using sodium boranocarbonate 
(Na2[H3BCO2]) as reductant and also as an in situ source of carbon monoxide. (46) 
Nowadays, the precursor [99mTc(H2O)3(CO)3]+ can be obtained in quantitative yield by 
directly adding [99mTcO4]- in 0.9% NaCl to a lyophilized commercial kit (IsoLink® kit, 
Mallinckrodt-Covidien, Petten, The Netherlands), followed by incubation at 100 °C for 20 
minutes. The ready availability of the precursor directly from the [99mTcO4]- constitutes 
one advantage of the use of this 99mTc(I)-tricarbonyl precursor. The preparation of the Re 
homolog [188Re(H2O)3(CO)3]+ was also accomplished, although using a procedure slightly 
different from that envolved the preparation of the Tc(I)-tricarbonyl precursor, since Re is 
more difficult to reduce and reacts, in general, much slower, as previously mentioned. 
(45,47) 
 
Figure 1.11 - Synthesis of the organometallic precursor [99mTc (H2O)3(CO)3]+. 
The [M(CO)3]+ core is stable, even at high temperature and extended reaction 
time.(48) Complexes of [M(CO)3]+ exhibit a d6 low-spin electronic configuration and, for 
that reason, are kinetically inert. The core contains three tightly coordinated CO ligands 
and three water molecules, which are very labile and can be readily replaced by mono-, bi- 
or tridentate chelators.(49) The tridentate chelators form 99mTc(I)-tricarbonyl complexes 
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with the highest in vivo stability, which is essential for medical applications.(50) The 
[M(CO)3]+ core is very compact, being significantly smaller than the complexes in the 
oxidation state (+V). This fact can be an advantage since it is thought that the smaller the 
complex, the higher the possibility that the biological activity will not be altered.(17,49)  
The three water molecules in the precursor fac-[99mTc(CO)3(H2O)3]+ are labile with 
respect to substitution, and the precursor can interact with potential coordination sites in 
proteins in human serum (e.g. histidine and cysteine residues). Therefore, the precursor 
itself is not suitable for diagnostic purposes, displaying a very unfavorable biological 
profile as demonstrated by biodistribution studies in mice. (51) Hence, to develop suitable 
radiopharmaceuticals based on this core, it is necessary to replace the water molecules by 
mono, bi, or tridentate ligands to form stable complexes. A wide variety of organometallic 
complexes have already been described, with those stabilized by tridentate chelating 
systems displaying the highest stability both in vitro and vivo. (52) In Figure 1.12 are 
represented selected complexes, stabilized by tridentate bifunctional chelators, bearing or 
not pendant targeting moieties. The diverse coordination chemistry of the [M(CO)3]+ core 
offers an opportunity for the development of new chelators.  
  
Figure 1.12 - Examples of M(CO)3-complexes stabilized by various types of chelating agents (BM = 
biomolecule; M = Re/99mTc). 1 - Functionalized cysteine (53); 2 - Funcionalized 2,3-diamino propionic acid 
derivatives (51); 3-Functionalized histidine derivatives (54,55); 4 – Cyclopentadienyl (56) ; 5, 6 and 7 - 
Functionalized picolinic acid derivatives (57,58); 8 – Triazacyclononane(59) ; 9 and 10 - Functionalized 
pyrazolyl-diamine containing ligands (60–64); 11 – Functionalized bis(mercaptoimidazolyl)borates.(65) 
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1.2.3. 99mTc Radiopharmaceuticals 
The 99mTc-based radiopharmaceuticals are roughly divided into two general 
categories,  as mentioned before. Examples of the perfusion agents, commercially available 
and respective clinical application are presented in Figure 1.13. (4,7,66) 
Myocardial Perfusion imaging 
A    99mTc-Sestamibi (cardiolite®) B   99mTc-tetrafosmin( Myoview®) 
  
Bone Imaging Renal Imaging 
C    99mTc-MDP(techneScan MDP®) D   99mTc-MAG3 (techneScan MAG3®) 
  
Brain Imaging 
E    99mTc-HMPAO (Ceretec®) F    99mTc-L,L, EDC (Neurolite®) 
 
 
 
Figure 1.13 - 99mTc-based radiopharmaceuticals for diagnosis in clinical use. (MDP = 
methylenediphosphonate, MAG3 = mercaptoacetyl-triglycine, HMPAO = hexamethylpropyleneamine 
oxime, EDC = cysteinate dimer). 
The growing demand for more specific 99mTc-radiopharmaceuticals has prompted 
the development of targeted radiopharmaceuticals mainly based on the BFC approach 
(Figure 1.8). As mentioned before, the targeting ability of specific radiopharmaceuticals 
relies on the capacity of the pendant biologically active molecule in the metal complex to 
recognize its target in vivo (e.g. membrane receptor, antigen or enzyme). (67–69) Besides 
the targeting moiety, also the spacer/linker between the metal and the biomolecule has a 
decisive influence in the overall biological properties of the radiopharmaceutical. (36) The 
modulation of the metal coordination environment with different chelators is a imperative 
parameter that opens great opportunities towards the design of innovative target specific 
radiopharmaceuticals with improved biological properties. Indeed, the design and 
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selection of the most appropriate BFC are the cornerstone for the development of 
clinically relevant imaging agents. Figure 1.14 shows selected Tc cores, which have been 
used for labeling different type BM with 99mTc. 
  
Figure 1.14 – Examples of Tc cores useful fort the labeling of biomolecules (BM) (6) 
The BM can be an antibody, a small peptide or a nonpeptidic molecule that can act 
as an agonist or antagonist of a specific receptor. (70) The most relevant examples of 
specific 99mTc-based radiopharmaceuticals approved for SPECT imaging are radiolabeled 
peptides: 99mTc-Depreotide (see figure 1.7) and 99mTc-Apcitide, figure 1.15. 
 
Figure 1.15 - 99mTc-Apcitide (Acutec®) 
1.3. Peptides in Molecular imaging 
To understand the role of peptides in molecular imaging is necessary to recognize 
how does a tumor cell and how is made the interaction between cells receptors and 
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peptides. The conformation of a tumor cell permits targeting different structures for 
imaging and therapy in oncology, see figure 1.16. 
 
Figure 1.16 – Summary of all unique targeting, diagnostic and therapeutic mechanisms as they relate to  
cancer cells.(67) 
Since the late 1980’s, peptides were synthesized to mimic natural ligands of 
receptors, and are being developed as tools for specific tumor cell targeting. Different 
kinds of receptors, e.g. hormone-, growth factor- or folate receptors, are often 
overexpressed in tumor cells, enabling discrimination between malignant and normal 
tissues. The much smaller size of tumor-specific peptide analogues compared to that of 
antibodies reveals several advantages: rapid tissue penetration combined with a rapid 
clearance; no antigenicity; easy synthesis and simple to be modified chemically. Moreover, 
peptides can be easily conjugated with chelates to enable radiolabelling with metallic 
radionuclides. (71) The overexpression of peptide receptors in human tumors has been of 
considerable clinical interest for the past 10 years. The most successful example is the 
overexpressed somatostatin receptors in human neuroendocrine tumors that can be 
targeted successfully. (72) 
Somatostatin receptors are overexpressed in neuroendocrine tumors. There are 
different subtipes of somastatin receptors built from 5 subtypes of somastotatin receptors 
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belonging to the G-protein coupled receptors; subtype 2 is the most widely overexpressed 
by tumors. (figure 1.17) 
 
Figure 1.17 - G-Protein-coupled receptor conformation in the cellular membrane.(73) 
Bombesin (BN), is a tetradecapeptide originally isolated from the skin of the 
European frog, Bombina bombina. It belongs to a large family of structurally related 
amphibian and mammalian peptides. BN has been shown to have potent physiological and 
behavioral effects in mammals, including the ability to suppress food intake. (74) 
  Although BN itself is not present in mammals, gastrinreleasing peptide (GRP) and 
neuromedin B (NMB) are two homologs that have been isolated from mammalian tissue 
and their receptors cloned and characterized. Structural and pharmacological differences 
have led to the identification of two BN receptor subtypes referred to as BB2 or GRP-
preferring (GRP-r) and BB1 or NMB-preferring (NMB-r). The GRP-r subtype preferentially 
binds GRP but has a low affinity for NMB, whereas the NMB-R subtype has a high affinity 
for the NMB and a lower affinity for GRP. BN binds with equal and high affinity to both 
receptor subtypes. (75) 
BN and its human counterpart GRP2 belong to a family of brain-gut peptides, 
shown, in addition to physiological effects, to play also an important role in cancer. It has 
been observed several years ago that cancer cell lines as well as primary human tumors 
can synthesize bombesin and GRP. (75) More recently, it has been shown that the GRP 
receptor proteins can be overexpressed in a large variety of human tumors, including 
prostate cancers, breast carcinomas, Small cell lung carcinomas (SCLCs), and non-SCLCs, 
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as well as renal cell carcinomas. Most of the studies up to now have been able to primarily 
identify the GRP receptor subtype, although it is known that the bombesin receptor family 
includes at least four different subtypes, namely the GRP receptor subtype (BB2), the NMB 
receptor subtype (BB1), and the BB3 and BB4 subtypes (16 –19). Except for the GRP 
receptor, the other three subtypes have been poorly characterized, in particular in regard 
to their distribution and function in human tissues. (76) 
There have been several studies about bombesin analogues in the past few years. 
Different research groups have studied these peptides, and there are new studies being 
published every year. (table 1.2) These studies involved a variety of approaches with the 
use of different chelators, linkers and peptide sequences for specific targeting of GRP-r. 
Table 1.2 - Sequences of various bombesin analogs. (76) 
Analogs Chelator Linker Sequences 
   1-6 7-13 14 
Bombesin - - 
pGlu-Gln-Arg-Leu-
GLy-Asn- 
-Gln-Trp-Ala-Val-Gly-His-Leu- -Met-NH2 
Demo-besin-
1 
N4 -BzDig- 
-D 
Phe- 
-Gln-Trp-Ala-Val-Gly-His-Leu-
NHEt 
 
BBS-1 (NxHis)Ac- -βAla-βAla-  -Gln-Trp-Ala-Val-Gly-His-Nle  
BBS-2 (NxHis)Ac- 
-Lys(sha)-βAla-
βAla- 
 -Gln-Trp-Ala-Val-Gly-His-Nle  
BBS-3 (NxHis)Ac- 
-Lys(Amd)-
βAla-βAla- 
 -Gln-Trp-Ala-Val-Gly-His-Nle  
BBS-4 (NxHis)Ac- 
-Ala(NTG)-βAla-
βAla- 
 -Gln-Trp-Ala-Val-Gly-His-Nle  
MP2653 DOTA  -aCMpip-Tha- 
-Gln-Trp-Ala-Val-βAla-His-
Tha- 
-Nle-NH2 
MP2346 DOTA  
-Pro-Gln-Arg-Tyr-
Gly-Asn- 
-Gln-Trp-Ala-Val-Gly-His-Leu- -Met-NH2 
Pesin DOTA -dPEG4-  -Gln-Trp-Ala-Val-Gly-His-Leu- -Met-NH2 
AMBA DOTA 
-CH2CO-Gly-4-
aminobenzyl 
 -Gln-Trp-Ala-Val-Gly-His-Leu- -Met-NH2 
RM 1 DOTA 
-CH2CO-Gly-4-
aminobenzyl 
-Phe- -Gln-Trp-Ala-Val-Gly-His-Sta- -Leu-NH2 
Lys(sha) = lysine-coupled shikimic acid, Lys(Amd) = Amadori-Product; Ala(NTG) = triazole-coupled glucose, Sta= 
statyl 
 
The first proof of concept of the clinical relevance of radiolabeled BN peptides for 
imaging and therapy of tumors was develop by Van de Wiele et al. (77), in year 2000. 
Following these studies, Lantry et al. (78) demonstrated that 177Lu-AMBA (DO3A-CH2CO-
G-(4-aminobenzoyl)-QWAVGHLM-NH2) binds with low nanomolar affinity to GRP-r. This 
compound showed good radiotherapeutic efficacy in PC-3 tumor bearing nude mice and 
effective targeting of primary prostate cancer in humans. (78)  
The analogues that have been studied are agonist and antagonist, as GRP-r can be 
targeted both by agonist and antagonist that belong to the family of bombesin peptides. 
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Whereas antagonists bind to GRP-r and remain on the surface of the tumor cells, typical 
agonists bind to GRP-r and are then internalized into the cells. (figure 1.18) (79)  
 
 
Figure 1.18 – Difference of agonists(a) and antagonists(b) of GRP-r. (80) 
In 2007, it was published a study using a pegylated bombesin agonist, DOTA-PESIN 
(DOTA-PEG4-BN (7–14)). In that study, it was shown that this radiopeptide has suitable 
pharmacokinetic properties for a potential use as diagnostic and therapeutic agent (81). 
However, the use of bombesin agonists in clinical studies is limited by the possible 
mitogenic properties of these compounds and by the side effects observed in patients 
undergoing escalation study. (82) 
Different classes of bombesin based antagonists were evaluated for their potential 
as targeting agents for diagnostic applications, such as PET, SPECT, and targeted peptide 
receptor radionuclide therapy (PRRT) of GRP-r positive tumors.(83–86) A first clinical 
study using the 64Cu-labeled statine-based bombesin antagonist 64Cu-CBC-AR-06 was 
recently reported by Wieser et al. showing suitable pharmacokinetics and good tracer 
accumulation in primary prostate cancer, in the four patients studied. (81) 
From 2013, there is a study of the effective potential of the statine-based bombesin 
antagonist RM2 in the treatment of PC-3 tumor bearing nude mice. Animals treated with 
177Lu-RM2 showed a significant inhibition of tumor progression leading to an increasing 
survival rate without treatment-related toxicity. (2) 
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There are many reports on the study of the influence of spacer, chelator and/or 
radiometal on the pharmacology of radiolabeled bombesin analogs, highlighting the 
importance of choosing the right combination of these factors in order to obtain suitable 
radiopeptides for diagnostic and therapeutic applications.(81,82,87) Rogers et al.  showed  
that a DOTA-PEG-Bombesin(7-14) derivative (PEG having a molecular weight of 3500kDa) 
lost about a factor of 103 in regard to GRP-r affinity but still showed good tumor uptake 
and pharmacokinetics. The importance of N-terminal charges and in particular of different 
spacer compositions were also demonstrated by Zhang et al. (81) and Yang et al. (88) 
Several 99mTc-labeled bombesin analogues have been investigated using the 
bifuntional approach and the tricarbonyl methodology, as exemplified in figure 1.19 for 
the conjugates [99mTc(CO)3-DTMA-(X)-BBN(7-14)NH2] obtained using the chelator DTMA 
(2-(N,N’-Bis(tert-butoxycarbonyl)diethylenetriamine) acetic acid). (89) 
 
Figure 1.19  - Struture of DTMA-(X)-BBN(7-14)NH2, where X=GGG(top), GSG, SSS and β-Ala (bottom). *GGG= 
AA Gly-Gly-Gly; GSG= Gly-Ser-Gly; SSS= Ser-Ser-Ser; 
In general the radioconjugates [99mTc(CO)3-DTMA-(X)-BBN(7-14)NH2] showed good 
results in terms of affinity to the GRP-r. However, as reported for other 99mTc/188Re-
tricarbonyl-based bombesin derivatives, they were predominantly cleared via the 
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hepatobiliary excretion pathway because of tricarbonyl’s inherent lipophilicity. Increasing 
the hydrophilicity of radiolabeled GRP-targeting peptide conjugates is necessary to avoid 
accumulation of radioactivity in the liver and intestinal tract, which  would compromise 
their capacity to effectively image solid tumors and metastatic lesions in the abdomen. 
Therefore, the finding of 99mTc-(CO)3 labeled BN derivatives with improved biodistribution 
profile still is an important issue in modern Radiopharmaceutical Sciences. 
1.4. Objective 
This thesis aimed to evaluate organometallic complexes of Tc(I) and Re(I) useful 
for the radiometalation of biologically active peptides. Due to the large spectrum of GRP 
receptor–expressing tumors, the bombesin receptor system is a clinically relevant target 
receptor system. Therefore, one of the goals was to investigate the radiolabeling of 
bombesin derivatives using the tricarbonyl approach. It was anticipated that the resulting 
radiopeptides should act as antagonists of GRPr. To accomplish this goal, we have 
synthesized different BFC’s for peptide conjugation and complexation of the (radio)metal. 
To evaluate the effect on the biological profile of the final radioconjugates, linkers of 
different length were used between the BFC’s backbone and the carboxylic function used 
for conjugation of the peptide. 
By exploring the pair Tc(I)/Re(I), is was taken into consideration the potential 
therapeutic applications of 186Re and 188Re. To concretize the strategy of development of a 
theranostic radiolabeled peptide, having at the same time imaging and therapeutic 
properties, it is necessary to improve the pharmacokinetic of the conjugates in order to 
have high ratio between target and non-target organs. Hence, as it is known that most of 
the 99mTc/188Re-tricarbonyl-based bombesin derivatives are very lipophilic, a PEG was 
attached to the N-terminal of the bombesin analogue, trying to enhance the hydrophilicity 
of the final compounds. 
 In the following chapters, it will be described the different steps to realize the 
aforementioned objectives, namely the strategies, synthetic procedures and studies 
involved in the synthesis and evaluation of the proposed compounds.  
  
 
 
 
  
  
 
 
 
 
 
2. Materials and 
Methods
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2.1 SOLVENTS AND REAGENTS 
All chemicals from commercial suppliers were of reagent grade or higher.  
The dry solvents used in this project were dried by distillation processes in C2TN 
laboratory and used for reactions under inert atmosphere. Tetrahydrofuran (THF) was 
freshly distilled from the sodium benzophenone ketyl radical ion. Acetonitrile (ACN), 
dichloromethane (DCM) were distilled from calcium hydride. Other solvents used in the 
experimental work were used as received. (90) 
The compound (2-Amino-ethyl)-carbamic acid tert-butyl ester (c4) and the 
organometallic precursor fac-[Re(CO)3(H2O)3]Br were prepared in the 
Radiopharmaceutical Sciences Group of C2TN (RSG-IST/C2TN) according to published 
methods. (91)Also the radioactive precursor [99mTc(CO)3(H2O)3]+ was prepared in the 
RSG-IST/C2TN,  according to the IsoLink manufacturer’s insert. (47) 
Table 2.1 - List of main solvents, reagents, AAs, and chemicals used in this work. 
 
Products Molecular Formula Manufacturer Cas-number 
S
o
lv
e
n
ts
 
Diclomethane(DCM) CH2Cl2 Sigma-Aldrich 75-09-2 
1,4-Dioxane C4H8O2 Sigma-Aldrich 123-91-1 
Acetone (CH3)COCH3 Carlo-Erba 67-64-1 
Acetonitrile (ACN) CH3CN Sigma-Aldrich 75-05-8 
Chloroform CHCl3 Scharlau 67-66-3 
Diethylether (CH3CH2)2º Sigma-Aldrich 60-29-7 
Ethanol (EtOH) CH3CH2OH Panreac 64-17-5 
Ethyl Acetate(EtOAc) CH3COOC2H5 Carlo-Erba 141-78-6 
Methanol (MeOH) CH3OH Carlo-Erba 67-56-1 
N,N-
Diisopropylethylamine 
(Dipea) 
[(CH3)2CH]2NC2H5 Sigma-Aldrich 7087-68-5 
N,N-Dimethylformamide 
(DMF) 
HCON(CH3)2 Carlo-Erba 68-12-2 
n-hexane CH3(CH2)4CH3 Sigma-Aldrich 110-54-3 
Petroleum ether C7H7BrMg Sigma-Aldrich 8032-32-4 
Piperidine C5H11N Sigma-Aldrich 110-89-4 
Tetrahydrofurane (THF) C4H8O Carlo-Erba 109-99-9 
Triethylamine (C2H5)3N Sigma-Aldrich 121-44-8 
Trifluoroacetic acid 
(TFA) 
CF3COOH Sigma-Aldrich 76-05-1 
Water H2O In house . 
Deuteraded 
solvents 
Deuterochloroform CDCl3 Sigma-Aldrich 865-49-6 
Tetradeuteromethanol CD3OD Euriso-top 811-98-3 
R
e
a
g
e
n
ts
 
Benzyl Bromoacetate C9H9BrO2 Sigma-Aldrich 5437-45-6 
1,2-dibromoethane BrCH2CH2Br Sigma-Aldrich 106-93-4 
1-Methyl-2-
imidazolecarboxaldehyde 
C5H6N2O Sigma-Aldrich 13750-81-7 
Di-tert-butyl dicarbonate 
(Boc protective group) 
[(CH3)3COCO]2O Sigma-Aldrich 24424-99-5 
Ethyl 4-bromobutyrate C6H11BrO2 Sigma-Aldrich 2969-81-5 
Ethylenediamine NH2CH2CH2NH2 Sigma-Aldrich 107-15-3 
Hydrochloric acid HCl Sigma-Aldrich 7647-01-0 
Magnesium sulfate 
anhydrous 96% 
MgSO4 Panreac 7487-88-9 
Potassium Carbonate K2CO3 Sigma-Aldrich 584-08-7 
Potassium Iodide KI Sigma-Aldrich 7681-11-0 
Pyrazol C3H4N2 Sigma-Aldrich 288-13-1 
Sodium borohydride NaBH4 Sigma-Aldrich 16940-66-2 
Sodium Hidroxide NaOH Sigma-Aldrich 1310-73-2 
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sodium 
triacetoxyborohydride 
(CH3COO)3BHNa Sigma-Aldrich 56553-60-7 
Tetrabutylammonium 
bromide (TBAB) 
(CH3CH2CH2CH2)4N(Br) Sigma-Aldrich 1643-19-2 
P
e
p
tid
e
 S
y
n
th
e
sis
 
HATU C10H15F6N6OP Sigma-Aldrich 148893-10-1 
FMOC-Ala-OH C18H17NO4 Novabiochem 35661-39-3 
FMOC-D-Phenylanine-OH C24H21NO4 Novabiochem 86123-10-6 
FMOC-Gln(Trt)-OH C39H34N2O5 Sigma-Aldrich 132327-80-1 
FMOC-Gly-OH C17H15NO4 Novabiochem 29022-11-5 
FMOC-His(Trt)-OH C10H15NO4 Sigma-Aldrich 109425-51-6 
FMOC-Leu-OH C27H23NO4 Novabiochem 35661-60-0 
FMOC-NH-PEG-COOH (9 
atoms) 
C21H23NO6 Novabiochem 166108-71 
FMOC-Sta-OH C23H27NO5 Novabiochem 158257-40-0 
FMOC-Trp(Boc)-OH C31H30N2O6 Sigma-Aldrich 143824-78-6 
FMOC-Val-OH C20H21NO4 Novabiochem 68858-20-8 
Rink Amide-MBHA Resin Novabiochem 431041-83-7 
Triisopropylsilane (TIS) [(CH3)2CH]3SiH Sigma-Aldrich 6485-79-6 
 
Table 2.2 - List of main devices used in this project. 
Device Name Description Manufacturer 
0.22 μm filters Sample preparation for 
HPLC system 
Millipore, Billerica, MA, USA 
300 or 400 MHz spectrometer NMR Varian Unity 300 or 400 MHz spectrometer 
99Mo/99mTc generator Elution  of 99mTc Drytec®, GE Healthcare 
Automatic analyzer EA 110 Elementary analysis CE Instruments, Ltd. Hindley Green 
Wigan. United Kingdom 
Buchi® R-210 Rotavapor® 
Evaporator 
Evaporation of Solvents Bunchi® Flawil Switzerland 
C18 reversed phase column 
(Nucleosil 10 μm, 250 x 4 mm) 
HPLC System Macherey-Nagel 
CEM 12-Channel Automated 
Peptide Synthesizer 
Peptide synthesizer CEM corporation. Qlabo Lda. Lisboa 
Discover and Explorer SP Microwave device CEM corporation. Qlabo Lda. Lisboa 
Discovery bio® wide pore C-
18 Column 
HPLC column Supelco. Sigma-Aldrich Co. LLC 
ionization chamber Radiation reader Curiemeter IGC-3, Aloka, Tokyo, Japan 
Lyophilizer Alpha I-12 Lyophilizer BODE & Co. Hamburg 
Mass Spectrometer MS Bruker HCT, Bilerica, MA, USA 
PerkinElmer Series 200 LC 
pump 
HPLC system PerkinElmer, Waltham, MA, USA 
Pump Vacuum line system Acatel, New Jersey, USA 
ultraviolet/visible (UV/Vis) 
detector 
HPLC system Shimadzu SPD-10AV, Shimadzu, Kyoto, 
Japan 
Vacuum Line Vacuum Lines system Rotaflo, England 
γ detector HPLC system Berthold-LB 509, Berthold Technologies, 
Bad Wildbad, Baden-Württemberg, 
Germany 
 
  
 28 
Organometalics Complexes of Tc(I) and Re(I) for  radiometalation of biological active  peptides Chapter 2 
2.2 PURIFICATION AND CHARACTERIZATION TECHNIQUES 
The purification and characterization methods used in this project are presented in 
this section and includes procedures of purification and characterization of organic 
compounds, as well as  methods used to characterize the 99mTc radiolabeled compounds. 
2.2.1. Gravity Column chromatography (GCC) 
When necessary, compounds were purified by gravity column chromatography 
(GCC) performed by using open glass columns loaded with silica gel (ASTM Merck 70-230 
mesh granulometry, 0.063-0.200mm). Columns with appropriate dimensions were used, 
depending on the amount of compound to purify; small vials were used to collect and 
separate the different fractions. The presence of the desired compound in the elution 
fractions was monitored by TLC and confirmed by 1H-NMR spectroscopy. 
2.2.2. Reversed-Phase High Performance Liquid Chromatography (RP-
HLPC) 
RP-HPLC analysis of compounds were performed on a PerkinElmer Series 200 LC 
pump coupled to an UV/VIS detector (PerkinElmer LC 290 or Shimadzu SPD-10AV) and to 
a γ detector (Berthold-LB 509). The organic eluents were of HPLC grade and the water 
was bidistilled in a quartz distillation unit. All solvents were purged with helium prior to 
use. The samples injected were pre-filtered with 0.22 μm filters (Millipore). 
 Two different elution methods (method 1 and 2) were used, according to the 
characteristics of the analyzed compounds. 
Method 1  
 Used in purification runs for peptide conjugates; 
 Discovery bio® wide pore C-18 (25cmx4,6mm; 5µm) reverse-phase column; 
 Flow: 1.0 mL/min or 2.0 mL/min;  
 U.V. detection: λ = 220 nm and 280nm  
 Eluents: A ‐ TFA 0.1 % in H2O; B ‐ TFA 0.1% in ACN 
  
 
 
 
 
 
Step 
Time 
(min) 
%A %B 
0 5 90 10 
1 0-45 900 10100 
2 47 90 10 
 
Table 2.3 – RP-HPLC method 1. 
Figure 2. 1 – RP-HPLC method 1 graphic profile. 
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Method 2  
 used in analytical runs for Re complexes and radiolabelling with 99mTc ; 
 Macherey-Nagel C18 reversed phase column (Nucleosil 10 μm, 250 x 4 mm); 
 Flow: 0.5 mL/min;  
 U.V. detection: λ = 220 nm  
 γ detection suited for 99mTc  
 Eluents: A ‐ TFA 0.1% in H2O; B ‐ CH3OH 
 
Step 
Time 
(min) 
%A %B 
0 5 100 0 
1 0-3 100 0 
2 3-3.1 10075 025 
3 3.1-9 75 25 
4 9-9.1 7566 2534 
5 9.1-20 660 34100 
6 20-25 0 100 
7 25-25.1 0100 1000 
8 25.1-30 100 0 
 
 
2.2.3. Thin-layer chromatography (TLC) 
Reactions were monitored by using thin layer chromatography (TLC) plates 
precoated with silica UV254 (60 F254 Merck silica gel, 0.2 mm). Visualization of the plates 
was carried out using UV light (254 or 365 nm) and/or iodine container, or a solution of 
2% ninhydrin (2,2-Dihydroxyindane-1,3-dione) in EtOH, followed by heating. 
2.2.4. Nuclear Magnetic Resonance (NMR) Spectroscopy 
The 1H, 13C or 19F-NMR (1D-NMR) and 1H-1H g-COSY (2D- NMR) spectra were 
recorded in a Varian Unity 300 or 400 MHz spectrometer. 
1H and 13C chemical shifts () were referenced to the residual solvent resonances 
relative to tetramethylsilane (SiMe4). The data are presented in ppm relative to the CDCl3 
solvent (1H,  7.26; 13C, 77.16) as internal standard or to the CD3OD solvent (1H 3.31; 
13C,  49.00). (92) 
2.2.5. Mass Spectrometry (MS) 
The electrospray-mass spectrometry (ESI-MS) analysis of compounds were 
obtained using an electrospray ionization/quadrupole ion trap (ESI/QIT) mass 
Table 2.4 – RP-HPLC method 2. 
Figure 2.2 – RP-HPLC method 1 graphic profile. 
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spectrometer (Bruker HCT, Bruker, Billerica, MA, USA) and were performed by Dr. Célia 
Fernandes from the C2TN. 
2.2.6. Spectrophotometry  
UV-vis absorption measurements were performed in a Shimadzu UV-1800 
Spectrophotometer (range: 200 – 1100 nm) at 280 nm, which the maximum absorption 
wavelength of the aminoacid triptofan.(93) 
2.2.7. Measurements of Radioactivity 
 The radioactivity of the 99mTc solutions was measured in an ionization 
chamber (Aloka, Curiemeter IGC-3). The samples with activity less than 2 μCi were 
measured in a Gamma Counter (Berthold LB 2111). 
2.2.8. Partition coefficient 
The partition coefficient was evaluated by the ‘‘shakeflask’’ method.(94) The 
radioconjugate was added to a mixture of octanol (1 mL) and 0.1 M PBS, pH 7.4 (1 mL) 
which had been previously saturated with each other by stirring. This mixture was 
vortexed and centrifuged (3,000 rpm, 10 min) to allow phase separation. Aliquots of both 
octanol and PBS were counted in a γ-counter. The partition coefficient in octanol/ water 
(log Po/w) was calculated by dividing the counts in the octanol phase by those in the 
buffer, and the results were expressed as log Po/w ± the standard deviation (S.D). 
2.2.9. Biodistribution studies 
All animal experiments were performed in compliance with national and European 
regulations for animal treatment. The animals were housed in a temperature- and 
humidity-controlled room with a 12 h light/12 h dark schedule.  
The biodistribution of the 99mTc complex Tc4 was evaluated in groups of 3 CD-1 
female mice (Charles River outbred strain, from IFFA CREDO, Barcelona, Spain). Mice were 
intravenously injected with 100 μl of complex Tc4 (3 - 10 MBq) via the tail vein and the 
animals were kept in normal diet ad libitum. Animals were sacrificed by cervical 
dislocation at 1 and 4 h after injection. The administered dose and the radioactivity in the 
sacrificed animals were measured with a dose calibrator (Curiemeter IGC-3, Aloka, Tokyo, 
Japan). The difference in radioactivity between the injected animal and the sacrificed 
animal was assumed to be due to excretion. Tissues and organs of interest were dissected, 
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rinsed to remove excess blood, weighted, and their radioactivity was measured using the 
dose calibrator. The uptake in the tissues or organs was calculated and expressed as 
percent injected dose per gram of tissue or organ (% IA/g). For blood, bone, muscle, and 
skin, total activity was estimated assuming that they represent 6, 10, 40, and 15 % of the 
total body weight, respectively. 
2.2.10. In Vivo stability studies 
The in vivo stability of the 99mTc(I) complexes was evaluated by RP-HPLC analysis 
of urine and blood.  
Urine: The urine collected at the sacrifice time was centrifuged at 3000 rpm for 15 
min and the supernatant was analyzed by RP-HPLC.  
Blood: The blood was collected at the sacrifice time, centrifuged at 3000 rpm for 
15 min at 4 °C, and the serum was separated. 100 μl aliquots of serum were sampled and 
treated with 200 μl of EtOH to precipitate the proteins. Samples were then centrifuged at 
3000 rpm for 15 min at 4 °C. The supernatant was analyzed by RP-HPLC. 
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2.3. SYNTHESIS OF LIGANDS 
2.3.2. Synthesis and characterization of N-2-bromoethyl-pyrazole - c1 
a bc
d
e
N
N Br
 
 
To a solution of pyrazole (10.51 g; 0.15 mol) in 1,2-dibromoethane (95 mL; 1.10 
mol) was added a solution of 40% NaOH (45 mL; 2.38 mol) and tetrabutylammonium 
bromide (TBAB) (1.20 g; 3.70 mmol) as a catalytic compound. After 24h of stirring at room 
temperature, the aqueous phase was extracted with CHCl3. The organic phase was dried 
over MgSO4, filtered and the solvent evaporated under vacuum. The resulting product was 
purified by distillation, under reduced pressure, and c1 was obtained as a colorless oil 
(19.03 g, 0.11 mol). 
Yield (η) = 70% 
Rf (Retention Factor) (CHCl3/ MeOH; 9:1) = 0.42 
1H-NMR (300 MHz, CDCl3; /ppm): 7.87 (s, 1H, CHc/e), 7.79 (s, 1H, CHc/e), 6.57 (s, 
1H, CHd), 4.80 (t, J = 6.2 Hz, 1H, CH2a), 4.03 (t, J = 6.2 Hz, 1H, CH2b). 
2.3.3. Synthesis and characterization of Synthesis and characterization of [2-(2-
Pyrazol-1-l-ethylamino)-ethyl]-carbamic acid tert-butyl ester - c2 
N
N N
H
HN Boc
a b
c
d
e
g h
i j
f
 
 
To a solution of c1 (1.01 g; 5.70 mmol) and triethylamine (1.73 g; 0.68 mL 6.70 
mmol) in dry ACN (25 mL) was added (2-Amino-etil)-carbamic acid tert-butyl ester (c4) 
(1.89 g, 4.68 mmol), which was synthetized as described in 2.3.6. After overnight reflux, 
the suspension was cooled down to r.t. and extracted with DCM. The organic phase was 
The percursor c1 was prepared as described in the literature. (97) 
Compound c2 was prepared as described in the literature. (63) 
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dried over MgSO4, filtered and the solvent evaporated under vacuum. The resulting 
product was purified by silica gel column chromatography, using CHCl3/MeOH (90/10) as 
eluent. After solvent evaporation of the collected fractions, c2 was obtained as pale yellow 
oil. 
η = 77%  
Rf (CHCl3/MeOH; 9:1) = 0.63 
1H NMR (300 MHz, CDCl3;ppm): 7.51 (s, 1H, CHc/e), 7.41 (s, 1H, CHc/e), 6.24 (s, 
1H, CHd), 5.01 (s, 1H, NHf), 4.22 (t, J = 5.5 Hz, 2H, CH2a), 3.16 (d, J = 5.0 Hz, 2H,CH2h), 3.04 (t, 
J = 5.4 Hz, 2H, CH2b), 2.70 (t, J = 5.4 Hz, 2H,CH2g ), 1.81 (s, 2H, NHi), 1.43 (s, 9H, (CH3)3j, Boc). 
2.3.4. Synthesis and characterization of 4-[(2-tert-Butoxycarbonylamino-
ethyl)-(2-pyrazol-1-yl-ethyl)-amino]-butyric acid ethyl ester - c3 
N
N N HN Boc
a
b
c
d
e
f
g
h
i j
k
l
O O
m
n
 
 
To a solution of c2 (0.93 g; 3.6 mmol) in dry ACN (30 mL) were added ethyl 4-
bromobutyrate (1.03 mL; 7.20 mmol; 1.4 g), K2CO3 (1.01 g; 7.2 mmol) and KI (0.1 mmol). 
After overnight reflux, the suspension was cooled down to r.t. and the solvent evaporated 
under vacuum. The resulting product was purified by silica gel column chromatography, 
using DCM/MeOH (95/5) as eluent. After solvent evaporation from the collected fractions, 
c3 was obtained as yellow oil. 
η = 75% 
Rf (CHCl3/MeOH; 9:1) = 0.73 
1H-NMR (300 MHz, CDCl3; /ppm): 7.42 (s, 2H, CH2c,e), 6.61 (s, 2H, CH2m), 6.15 (s, 
1H, CHd), 4.10 (s, 2H, CH2a), 2.98 (s, 2H, CH2b), 2.79 (s, 2H, CH2h), 2.43 (s, 2H, CH2f), 2.37 (s, 
The percursor c3 was prepared as described in the literature. (63) 
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2H, CH2g), 2.17 (s, 1H, NHi), 2.04 (s, 2H, CH2l), 1.54 (s, 2H, CH2k), 1.38 (s, 9H, (CH3)3j=Boc), 
1.25 (t, J = 7.1 Hz, 3H, CH3n). 
2.3.5  Synthesis and characterization of 4-[(2-tert-Butoxycarbonylamino-ethyl)-
(2-pyrazol-1-yl-ethyl)-amino]-butyric acid – L1-Boc 
N
N N HN
COOH
Boc
L1-Boc
a
b
c
d
e
f
g
h
i j
k
l
 
 
Compound c3 was dissolved in THF (15 mL) and to the resulting solution was 
added an excess of NaOH (8.07 mmol) in H2O (5 mL). After overnight reflux, the 
suspension was cooled down to r.t., neutralized with 1M HCL (7 mL) and the solvent 
evaporated. The obtained residue was extracted with DCM. The organic phase was dried 
over MgSO4, filtered and the solvent evaporated. The resulting product was purified by 
silica gel column chromatography, using CHCl3/MeOH (80/20) as eluent. After 
evaporation of the solvent from the collected fractions, L1-Boc was obtained as yellow oil. 
η = 78% 
Rf (CHCl3/MeOH; 9:1) = 0.71 
1H-NMR (300 MHz, CDCl3; /ppm): 7.42 (s, 2H, CH2c,e), 6.61 (s, 2H, CH2m), 6.15 (s, 
1H, CHd), 4.10 (s, 2H, CH2a), 2.98 (s, 2H, CH2b), 2.79 (s, 2H, CH2h), 2.43 (s, 2H, CH2f), 2.37 (s, 
2H, CH2g), 2.17 (s, 1H, NHi), 2.04 (s, 2H, CH2l), 1.54 (s, 2H, CH2k), 1.38 (s, 9H, (CH3)3j=Boc).  
13C NMR (300 MHz, CDCl3, /ppm): 184.7 (CO), 173.2 (CO), 142.9 (Cc), 135.6 (Ce), 
122.4 (Cd), 83.1 (C(CH3)) 55.2 (Cl), 54.6 (Cg), 52.3 (Cb), 50.1 (Ca), 39.1 (Ch), 37.1 (Cf), 29.7 
(C(CH3)), 24.3(Ck). 
 
 
The ligand L1-Boc was prepared as described in the literature. (63) 
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2.3.6. Synthesis and characterization of (2-Amino-etil)-carbamic acid tert-
butyl ester – c4 
HNH2N Boc
a b
c
d
e
 
 
A solution of di-tert-butyl dicarbonate ((Boc)2O) (13.93 g, 63.80 mmol) in 1,4-
dioxane (100 mL) was drop wise added to ethylenediamine (22.47 g, 0.37 mol) in 1,4-
dioxane (80 mL). After overnight with strong stirring at r.t., the solvent was evaporated 
and the residue extracted with CHCl3. The organic phase was filtered, dried with MgSO4 
and evaporated.  After evaporation, c4 was obtained as pale white oil. 
η = 74% 
Rf (CHCl3/MeOH; 9,8:0,2) = 1 (solvent front) 
1H NMR (400 MHz, CDCl3; /ppm): 5.59 (s, 1H, NHd), 2.87 (s, 2H, CH2a), 2.50 (s, 
CH2b), 1.21 (s, 2H, NH2c), 1.16 (s, 9H, (CH3)3j=Boc). 
13C NMR (400 MHz, CDCl3; /ppm): 28,03 ((CH3)3, Boc); 41,49 (CH2a); 43,06 (CH2b); 
78,51 (C-Boc);156,00 (C=O, Boc) 
 
2.3.7. Synthesis and characterization of (2-(1-Methyl-1H-imidazol-2-
ylmethyl)-amino)-ethyl)-carbamic acid tert-butyl ester – c5 
HNN
H
N
N
abc
d
e
f
g
h
k
m
i
j
l
n
O
O
 
To a solution of c4 (3.1 mmol) in dried MeOH (20 mL) was added 1-methyl-2-
imidazolecarboxaldehyde (3.1 mmol). The solution was refluxed during 3h and then 
stirred overnight at r.t., under N2 atmosphere. Then, a solution of NaBH4 (9.3 mmol) in 
MeOH (10 mL) was added to the mixture. After one more night of stirring at r.t., the 
The percursor c7 was prepared as described in the literature. (109) 
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solvent was evaporated and the residue extracted with DCM. The organic phase was 
filtered, dried with MgSO4 and evaporated. After solvent evaporation, the residue was 
extracted with diethyl ether and the obtained suspension was separated by centrifugation 
(3500 rpm, 8 min) and the organic phase evaporated to afford c5 as white oil. 
η = 97% 
Rf (CHCl3/MeOH; 9,8:0,2) = 0.31 
1H-NMR (300 MHz, CDCl3; /ppm): 6.94 (s, 1H, CHe), 6.83 (s, 1H, CHf), 5.18 (s, 1H, 
NHi), 3.90 (s, 2H, CH2c), 3.68 (s, 3H, CH3d), 3.46 (t, J = 9.4 Hz, 1H, NHh ), 3.33 – 3.17 (m, 2H, 
CH2a), 2.83 (t, J = 5.8 Hz, 2H, CH2b), 1.43 (s, 9H, (CH3)3m,n,l, Boc). 
13C-NMR (300 MHz, CDCl3;/ppm): 156.21 (C=Oj, Boc), 146.33 ( Cg ), 127.12 ( Ce), 
121.26 (Cf), 79.13 (Ck), 48.83 (Cb), 45.19 (Ca), 32.70 (Cc), 28.45 (Cl,m,n, Boc), 28.39 ( CH3d). 
ESI-MS (+) (mass/charge-m/z): 255.3 [M+H]+, calculated for C12H22N4O2 = 254.17 
 
2.3.8. Synthesis and characterization of N-(1-metyl-1H-imidazol-2ylmethyl)-
ethane-1,2-diamine – L5 
H2NN
H
N
N
abc
d
e
f
g
h
i  
 To a solution of c5(0.79 mmol) in DCM (10 mL) was added TFA (1 mL, 13.06 
mmol). The reaction mixture was stirred overnight at room temperature. The solvent was 
removed under vacuum and the resulting product, L5, was obtained as white oil.  
η = 64% (for L5·TFA) 
Rf (CHCl3/MeOH; 9,8:0,2)  = 0,43 
1H-NMR  (400 MHz, CD3OD; /ppm): 6.86 (s, 1H, CHe/f), 6.74 (s, 1H, CHe/f), 3.71 (s, 
2H, CH2c), 3.59 (s, 1H, NHi), 3.57 (s, 3H, CH3d), 2.61 (t, J = 5.7 Hz, 2H, CH2a), 2.55 (t, J = 5.7 
Hz, 2H, CH2b). 
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13C-NMR (400 MHz, CD3OD; /ppm): 163.41 (Cd), 120.07 (Cf), 116.19 (Ce), 56.53 
(Cb), 45.06 (Ca), 41.00 (Cc), 33.09 (Cd).  
19F-NMR (400 MHz, CD3OD;/ppm): -77.05 (TFA)  
ESI-MS (+) (mass/charge-m/z): 155.8 [M+H]+, 177.3 [M+Na]+, 269.3 [M+TFA+H]+ , 
calculated for C7H14N4 = 154.12 
 
2.3.9. Synthesis and characterization of  benzyl 2-(2-(tert-
butoxycarbonylamino)ethylamino)acetate – c6 
j
k
l
a b
c de
f
g
h
i
NH HN
O
O
Boc
 
 
To a solution of c4 (0.95 g, 5.9 mmol) and triethylamine (0.59 g; 0.83 mL; 5.92 
mmol) in ACN (20.0 mL) was added benzyl bromoacetate (1.28 g; 0.88 mL; 5.91 mmol) via 
syringe over 3 min. After 3h, the reaction mixture was diluted with 40 mL of EtOAc and 
washed with 40 mL of 2M K2CO3 (aq.). The organic phase was separated, then brine was 
added and the organic phase separated again. The organic phase  was dried with Na2SO4, 
filtered and the solvent evaporated. The resulting product was purified by silica gel 
column chromatography, using CHCl3/MeOH (98/2) as eluent. After solvent evaporation 
from the collected fractions, c6 was obtained as yellow oil. 
η = 38% 
Rf (CHCl3/MeOH; 9,8:0,2)  = 0,55 
1H-RMN (300 MHz, CDCl3; /ppm): 7.35 (s, 5H, (CH)5h-l, Benzyl), 5.17 (s, 2H, CH2g), 
5.02 (s, 1H, NHe), 3.49 (s, 2H, CH2f), 3.23 (s, 2H, CH2a), 2.79 (s, 2H, CH2b), 2.18 (s, 1H, NHc), 
1.44 (s, 9H, (CH3)3d, Boc). 
The precursor c6 was prepared as described in the literature. (110) 
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2.3.10. Synthesis and characterization of [(2-tert-Butoxycarbonylamino-ethyl)-
(1-methyl-1H-imidazol-2-ylmethyl)-amino]-acetic acid benzyl ester – c7  
j
k
l
a
bc
d
e
f
g
h
i
O
O
N
HN
N
N
s
m
r
t
n
O
O
o
p
q
u
v  
 
To a solution of c6 (0.23 g, 0.723 mmol) in dried DCM (20 mL) was added 1-
methyl-2-imidazolecarboxaldehyde (79.63 mg; 0.723 mmol) and sodium 
triacetoxyborohydride (0.21 g; 1.01 mmol). After overnight reflux under N2, a saturated 
aqueous sodium hydrogen carbonate solution was added, and the mixture stirred for 15 
min prior to extraction with ethyl acetate. The organic phase was filtered, dried with 
MgSO4 and evaporated. The resulting product was purified by silica gel column 
chromatography, using CHCl3/MeOH (98/2) as eluent. After solvent evaporation from the 
collected fractions, c7 was obtained as transparent oil. 
η = 55% 
Rf (CHCl3/MeOH; 9,8:0,2) = 0.24 
1H NMR (400 MHz, CDCl3; /ppm): 7.28 (s, 5H, (CH)5l-p, Benzyl), 6.85 (s, 1H, CHf/g), 
6.77 (s, 1H, CHf/g), 5.39 (s, 1H, NHq), 5.06 (s, 2H, CH2j), 3.81 (s, 2H, CH2c), 3.61 (s, 3H, CH3e), 
3.36 (s, 2H, CH2h), 3.09 (d, J = 4.4 Hz, 2H, CH2a), 2.68 (t, J = 5.3 Hz, 2H, CH2b), 1.38 (s, 9H, 
(CH3)3t,u,v, Boc). 
13C NMR (400 MHz, CDCl3;/ppm): δ 169.47(C=Or, Boc), 154.35 (C=Oi), 142.90 
(Cd), 133.80 (Ck), 126.87 (Co,m), 126.65 (Cn), 126.58 (Cl,p), 125.16 (Cf), 120.16 (Cg), 75.76 
(Cj), 64.67 (Ch), 52.97 (Cb), 51.98 (Cc ), 49.17 (Ca), 36.57 (Cs), 31.05 (Ce), 26.73 (Ct,u,v, Boc). 
ESI-MS (+) (mass/charge-m/z): 403.4 [M+H]+, 425.2 [M+Na]+  calculated for 
C21H30N4O4= 402,23. 
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2.3.11. Synthesis and characterization of {(2-tert-Butoxycarbonylamino-ethyl)-
[2-(2H-pyrazol-1-yl)-ethyl]-amino}-acetic acid benzyl ester – c8  
NN HN
N
O
O
a
bc
d
e
f
g
h
i
o
p
q
v
u
t s
r
j O
O
k
l
m
n
 
To a solution of c6 (0.19 g; 0.62 mmol) in dried ACN (30 mL) were added 
compound c1 (0.12 g; 0.62 mmol), K2CO3 (85.6 mg, 0.62 mmol) and KI (0.01 mmol). After 
100h of reflux, the suspension was cooled down to r.t. and the solvent evaporated. The 
resulting product was purified by silica gel column chromatography, using CHCl3/MeOH 
(98/2) as eluent. After solvent evaporation from the collected fractions, c8 was obtained 
as an yellow oil. 
η = 81% 
Rf (CHCl3/ MeOH; 9,5:0,5) = 0.59 
1H-RMN (400MHz, CD3OD; /ppm): 7.32 (s, 1H, CH, Ce), 7.33 (s, 1H, Cc), 7,34 (m, 
5H, (CH)5r-v, Benzyl), 6.27(s,1H, CHd), 5.14 (s, 2H, CH2p), 4.49 (m, 2H, CH2a), 3.43 (m, 4H, 
(CH2)2b,g), 3.23 (s, 4H, (CH2)2f,h), 1.53 (s, 1H, CHi), 1.44 (s, 9H, (CH3)3 l,m,n, Boc) 
13C NMR (400 MHz, CDCl3; /ppm): 171.12 (C=Oj, Boc), 156.06 (C=Oo), 139.43 (Cc), 
135.53 (Cq), 129.83 (Ce), 128.60 (Cu,s), 128.40 (Ct), 128.34 (Cv,r), 105.36 (Cd), 77.36 78.85 
(Cp), 66.34 (Cf), 54.71 (Cg), 54.27 (Cb), 53.64 (Ca), 50.66 (Ch), 38.35 (Ck), 28.45 (Cl,m,n, Boc). 
2.3.12. Synthesis and characterization of 4-(2-tert-Butoxycarbonylamino-
ethylamino)-butyric acid ethyl ester – c9  
HN
HN
O
O
Boc
a
b
c
d
e
f
g
h
i
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To a solution of c4 (0.19 g; 0,62 mmol), K2CO3 (85.60 mg, 0.62 mmol) and KI (0.01 
mmol) in dried ACN (20 mL) was added drop-wise 4-bromo- ethyl butyrate (0.12 g; 0.62 
mmol). After 48h reflux, under N2 atmosphere, the suspension was cooled down to r.t. and 
the solvent evaporated. The resulting product was purified by silica gel column 
chromatography, using CHCl3/MeOH (98/5) as eluent. After solvent evaporation, the 
purified compound wasn’t isolated and it was performed other column chromatography 
with silica gel, using EtOAc/n-hexane (90/10). After solvent evaporation from the 
collected fractions, c9 was obtained as an brown oil. 
η = 9% 
Rf (EtOAc/n-hexane; 9:1)  = 0,48 
1H-RMN (400MHz, CD3OD; /ppm): 4.87 (s, 1H, NH), 4.13 (p, J = 7.1 Hz, 2H, CH2h), 
3.45 (dd, J = 12.9, 5.9 Hz, 2H, CH2b), 3.42 – 3.34 (m, 4H, CH2a,f), 3.34 – 3.24 (m, 2H, CH2e), 
2.38 (t, J = 8.1 Hz, 2H, CH2g), 1.44 (s, 3H,CH3i), 1.42 (s, 9H, (CH3)3c), 1.25 (dd, J = 13.9, 6.7 Hz, 
1H, NHd). 
ESI-MS (+) (mass/charge-m/z): 275.4 [M+H]+ calculated for C21H30N4O4= 274,36. 
 
2.3.13. Synthesis and characterization of [(2-tert-Butoxycarbonylamino-ethyl)-
(1-methyl-1H-imidazol-2-ylmethyl)-amino]-acetic acid – L3.3-Boc 
a
bc
d
e
f
g
h
i
OH
O
N
H
NN
N
l
k
m
O
O
j
n
o
p
L3-Boc  
 
A solution of c7 (0.16 g, 0.51 mmol) and 10% Pd/C (54.20 mg, 0.41 mmol) in 
MeOH (50 mL) at r.t. was placed under an atmosphere of hydrogen. After 7h, the mixture 
was filtered through Celite using MeOH as eluent, and concentrated under reduced 
pressure, to afford compound L3-Boc as orange oil. 
η = 94% 
Rf (CHCl3/MeOH; 9,5:0,5) = 0.30 
The percursor L3.3-Boc was prepared as described in the literature. (111) 
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1H NMR (400 MHz, CDCl3; /ppm): 6.88 (s, 1H, CHf/g), 6.87 (s, 1H, CHf/g), 6.69 (s, 
1H,OHp), 3.64 (s, 2H, CH2b), 3.56 (s, 2H, CH2a), 3.33 (s, 3H, CH3e), 2.95 (s, 2H, CH2c), 2.95 (s, 
1H, NHj), 2.48 (s, 2H, CH2h), 1.33 (s, 9H, (CH3)3m,n,o, Boc). 
13C NMR (400 MHz, CDCl3; /ppm): 176.85 (C=Oi), 156.42 (C=Ok, Boc), 146.04 (Cd), 
127.01(Cf), 121.10 (Cg), 78.59 (Ce), 77.36 (Ch), 53.83 (Ca), 49.90 (Cb), 32.78 (Cc), 28.68 (Ce), 
28.57 (Cm,n,o, Boc). 
ESI-MS (+) (mass/charge-m/z): 313.4 [M+H]+ and 351.3 [M+K]+ calculated for 
C14H24N4O4= 312,18. 
2.3.14. Synthesis and characterization of [(2-tert-Butoxycarbonylamino-ethyl)-
(2-pyrazol-1-yl-ethyl)-amino]-acetic acid – L2-Boc 
L2-Boc
NN HN
N
a
bc
d
e
f
g
h
i
k
o O
HO
j O
O
k
l
m
n
 
 
A solution of c8 (192 mg; 0.47 mmol) and 10% Pd/C (50 mg; 0.47 mmol) in MeOH 
(50 mL) at r.t. was placed under hydrogen atmosphere. After 7 h, the mixture was filtered 
through Celite using MeOH as eluent, and concentrated under reduced pressure, to afford 
compound L2-Boc as a orange oil. 
η = 94% 
Rf (CHCl3/MeOH; 9,5:0,5) = 0.59 
1H NMR (400 MHz, CDCl3; /ppm) : 9.31 (s, 1H, OH), 7.46 (d, J = 15.6 Hz, 2H, 
(CH)2c,e), 6.20 (s, 1H, CHd), 5.39 (s, 1H,NHi), 4.20 (s, 2H, CH2a), 3.29 (s, 2H, CH2f), 3.07 (s, 
4H,(CH2)2b,g), 2.72 (s, 2H, CH2h), 1.38 (s, 9H, (CH3)3l,m,n, Boc). 
13C NMR (400 MHz, CDCl3;  /ppm): 173.65(C=Oj), 156.29 (C=Oo), 139.49 (Cc), 
130.23(Ce), 105.68 (Cd), 79.10 (Ck), 77.36 (Cf), 54.50 (Cg), 54.16 (Ca), 49.49 (Cb), 37.92 (Ch), 
28.43 (Cm,n,l, Boc). 
ESI-MS (+) (mass/charge-m/z): 313.4 [M+H]+  calculated for C14H24N4O4=  312,18. 
The ligand L2-Boc was prepared using a similar procedure described in the literature. (111) 
 42 
Organometalics Complexes of Tc(I) and Re(I) for  radiometalation of biological active  peptides Chapter 2 
2.4. SYNTHESIS AND CHARACTERIZATION OF BOMBESIN ANTAGONIST PEPTIDES 
AND CONJUGATES 
Table 2.5 – Summary of procedures in Solid Phase Peptide Synthesis (SPPS). 
 
 
 
 
 
2.4.1. Synthesis of Bombesin Antagonist (AR) peptide 
NH2
O
HN
O
OH
N
H
O
N NH
H
N
O
N
H
O
H
N
O
N
H
O
HN
H
N
O
N
H
NH2
O
O
H2N
Trp3
His7
Sta8 Leu9
Gly6Val
5Ala
4
Gln2
D-Phe1
 
 
The fully protected AR peptide (DPhe1-Gln2-Trp3-Ala4-Val5-Gly6-His7-Sta8-Leu9-
NH2.) was prepared by Fmoc-based Solid Phase Peptide Synthesis in a CEM 12-Channel 
Automated Peptide Synthesizer (scale 0.1 mM), using a Rink Amide-MBHA resin 100 – 200 
mesh (0.97g; substitution: 0.65 mmol/ g) and the following side chain protecting groups: 
Boc for Trp and Trt for His and Gln.  
The peptide was cleaved from the resin. The cleavage solution was separated from 
the resin by filtration and concentrated under N2. The crude peptide was precipitated and 
washed with ice-cold diethylether, vacuum-dried, and dissolved in water before 
lyophilization. 
ESI-MS (+) (m/z): 557.7 [M+2H]++, 976.9 [M-His], 1130.4 [M+NH4]+ , 1130.4 
[M+H2O]+ calculated for C55H80N14O11 = 1112.61 
Procedure Addition Time Cycles 
Swelling 
2.0 mL DMF 15 min 1 
2.0 mL DMF 60 min 1 
Fmoc Deprotection 
2.0 mL 25% piperidine/DMF 3 min 1 
2.0 mL 25% piperidine/DMF 12 min 1 
Washing 2.0 mL DMF 1 min 5 
To store the resin dry 2.0 mL DCM 5 min 2 
Cleavage 2.0 mL 95%TFA, 2.5% Tis and 2.5% H2O 2-3h 1 
Coupling 
1eqv of Resin 
3 eqv of coupler 
4 eqv of Activator (HBTU or HATU) 
7 eqv of Base (Dipea) 
3h 2x 
The AR peptide was prepared using a similar procedure to that  described in the literature. (87) 
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2.4.2. Synthesis of AR peptide conjugated with polyethyleneglycol (PEG2) 
(ARPEG2) 
NH2
O
HN
O
OH
N
H
O
N NH
H
N
O
N
H
O
H
N
O
N
H
O
HN
H
N
O
N
H
NH2
O
O
H
N
Trp3
His7
Sta8 Leu9
Gly6Val
5Ala
4
Gln2
D-Phe1
O
O
O
H2N
PEG2
 
 The AR peptide in solid phase, obtained as described in section 2.4.1, (0.39 g; 
0.25 mmol), was suspended in DIPEA (342 μL)/DMF (250 μL) and added to the 
commercial reagent PEG2 (0.39 g; 1.01 mmol) pre-incubated during 15 min with HATU 
(0.29 g; 0.76 mmol) in DMF. The pH was followed and the reaction mixture was left under 
stirring at room temperature for 3 hours. Then, another coupling cycle was repeated using 
the same conditions. The kaiser test (see section 2.4.9) was performed with a negative 
result for free amine groups. After cleavagefrom the resin using the standard cocktail 
mixture (95% TFA, 2.5% TIS, 2.5% H2O) the compound, ARPEG2, was precipitated with 
ice-cold diethylether. The precipitate was dried under N2 flow and dissolved in water 
before lyophilization.  
ESI-MS (+) (mass/charge-m/z): 1123.1 [M-His]+, 1258.9 [M+H]+ and 1298.5 
[M+ACN]+ calculated for C61H91N15O14 = 1257.9 
RP-HPLC (Method 2): Rt=15.84 min. 
2.4.3. Synthesis of L4  
NH2
O
HN
O
OH
N
H
O
N NH
H
N
O
N
H
O
H
N
O
N
H
O
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H
N
O
N
H
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O
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O
O
O
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H
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N N
N
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 The FMOC group of ARPEG2 in solid phase, not submitted to any purification, 
was deprotected with a solution of 25% piperidine/DMF. After 15 min. stirring, the 
ARPEG2 containing resin (0.05 g;, 0.03 mmol) was suspended in DIPEA (200 μL)/DMF 
(250 μL) and added to the Boc-protected bifunctional chelator L1-Boc (0.08 g; 0.24 mmol) 
pre-incubated during 30 min with HATU (0.13 g; 0.35 mmol) in dry DMF. The solution was 
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submitted to three cycles of microwave irradiation (40 W, 75ºC, 5 min). The residue was 
deprotected with the standard cocktail mixture (95% TFA, 2.5% TIS, 2.5% H2O) and 
precipitated with ice-cold diethylether. The precipitate was dried under nitrogen flow and 
dissolved in water before lyophilization. The reaction mixture was purified by semi-
preparative RP-HPLC (Method 1). The HPLC fraction corresponding to the compound was 
collected and evaporated. After analytical purification and evaporation of solvents from 
the corresponding fractions, L4 was obtained as a white solid. 
 ESI-MS (+) (mass/charge-m/z): 1481.5 [M+H]+ calculated for C72H109N19O15 = 
1479.84 
 RP-HPLC (Method 1): Rt = 34.2 min; (Method 2) 98.5 % Rt=20.00 
 
2.4.4. Attempted synthesis of L6 
NH2
O
HN
O
OH
N
H
O
N NH
H
N
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H
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O
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N
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 The coupling of the peptide conjugate L6 was done using the same procedure as 
for the synthesis of L4, described in section 2.4.3. The ligand, L2-Boc (52.40 mg; 0.17 
mmol) was pre-incubated with the activator HATU (63.95; 0.17mmol) was coupled with 
the peptide conjugated ARPEG2 in resin, pre-deprotonated with Dipea (80µL; 0.45 mmol) 
by microwave technology (40 W, 75ºC, 5 min).  
 ESI-MS (+) (mass/charge-m/z): calculated for C70H105N19O15 = 1451,8. 
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2.4.5. Attempted synthesis of L7 
 
NH2
O
HN
O
OH
N
H
O
N NH
H
N
O
N
H
O
H
N
O
N
H
O
HN
H
N
O
N
H
NH2
O
O
H
N
Trp3
His7
Sta8 Leu9
Gly6Val
5Ala
4
Gln2
D-Phe1
O
O
O
HN
PEG2
O
H2N
N
N
N
L3.3
 
The coupling of the peptide conjugate L7 was done as the same procedure for 
the synthesis of L4, described in section 2.4.3. L3.3-Boc (50.90 mg; 0.16 mmol) was pre-
activated with the activator HATU (62.10; 0.16 mmol) and coupled to ARPEG2 in resin, 
with Dipea as base (80µL; 0.43 mmol) by microwave technology (40 W, 75ºC, 5 min). 
ESI-MS (+) (mass/charge-m/z): calculated for C70H105N19O15 = 1451,8. 
 
2.4.6. Cleavage of Bombesin Antagonist and Resin 
The AR and derivatives were cleaved and removed from the resin and 
remaining lateral protection groups, using a deprotection cocktail of 2mL 
TFA:TIS:H2O (v/v) (95 : 2.5:2.5), mixed for 2h-3h. 
 
2.4.7. Precipitation of Bombesin Antagonist Derivatives  
Diethyl ether at -18: C was added to the collected product and centrifuged at 3,500 
rpm at 4:C during 10 min. The solvent was disposed of and this procedure repeated 
twice. The product was liophilizated overnight, and the dry product was st ored at -
18:C. 
2.4.8. HPLC analysis and Purification of Bombesin Antagonist 
Derivatives 
The synthesized product was analyzed and purified by RP-HPLC, Method 1, 
described in section 2.2.2 . 
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For all tested compounds, HPLC runs were performed with detection at 220 nm 
(wavelength of peptide bond absorption) and 280 nm (wavelength of tryptophan 
absorption). (93) 
After purification the collected fractions were evaporated and then freeze dried in the 
lyophilizer then the dry product was stored at -18:C. 
2.4.9. Kaiser Test  
SPPS when performed manually is necessary to assess the coupling with the 
formation of the amide bond and also the deprotection reactions. This evaluation is done 
through a Kaiser Test (Ninhydrin  Test). Kaiser Test consist in testing a small sample of 
resin with a solution of 5% ninhydrin in ethanol, 80% phenol in ethanol and potassium 
cyanide (KCN) in pyridine (2mL 0.001 KCN in 98mL pyridine), followed by heating. (95) 
This qualitative test involve the comparison of the color with reference solutions. 
(Table 2.7). The appearance of the color blue when the α-AA is deprotected is due to 
formation of Ruhemann complex.  
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Table 2.6 – Color patterns of Kaiser test. 
 
Colorless or faint blue color 
 complete coupling, 
 proceed with synthesis 
 
 
Solution yellow 
 
Dark blue solution but beads are 
colorless 
 nearly complete coupling, 
 extend coupling or 
capunreacted chains 
Solution is light blue but beads are 
dark blue 
 coupling incomplete, 
 recouple 
Solution is intense blue and all 
beads are blue 
 failed coupling, 
 check amino acid, reagents, 
then recouple 
2.4.10. Handling and Storage of Peptides 
Peptides have widely varying solubility properties. The main problem 
associated with the dissolution of a peptide is secondary structure formation. This 
formation is likely to occur with all , but the shortest of peptides and is even more 
pronounced in peptides containing multiple hydrophobic amino acid residues. 
Secondary structure formation can be promoted by salts. It is recommended first to 
dissolve the peptide in sterile distilled or deionized water. Sonication can be applied 
if necessary to increase the rate of dissolution. If the peptide is still insoluble, addition 
of a small amount of dilute (approximately 10%) acetic acid (for basic peptides) or 
aqueous ammonia (for acidic peptides) can facilitate dissolution of the peptide.  
For long-term storage of peptides, lyophilization is highly recommended. 
Lyophilized peptides can be stored for years at temperatures of -20°C or lower with 
little or no degradation. Peptides in solution are much less stable. Peptides are 
susceptible to degradation by bacteria so they should be dissolved in sterile, purified 
water. 
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Peptides containing methionine, cysteine, or tryptophan residues can have 
limited storage time in solution due to oxidation. These peptides should be dissolved 
in oxygen-free solvents. To prevent the damage caused by repeated freezing and 
thawing of peptides, dissolving the amount needed for the immediate experiment and 
storing the remaining peptide in solid form is recommended.(96) 
All the peptides used in this project follow the previous recommendations.  
 
2.5. SYNTHESIS AND CHARACTERIZATION OF THE RE(CO)3-COMPLEXES 
2.5.1. Rhenium complex fac-[Re(CO)3(κ3-L4)]+ (Re4) 
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Briefly, L4 (0.60 mg, 0.4x10-3 mmol) reacted with the organometallic precursor 
[Re(CO)3(H2O)3]Br (0.30 mg, 0.7x10-3 mmol) in MeOH in reflux for 72 h and with pH 
adjustment with NaOH from 5 to 9-10. After evaporation of the solvent the resulting 
residue was purified by preparative RP-HPLC (Method 2).  
 ESI-MS (+) (mass/charge-m/z): 1751 [M+H]+, calculated for C75H109N19O18Re+ = 
1749,84 . 
 RP-HPLC (Method 2): Rt = 23,17 min  
2.5.2. Rhenium complex fac-[Re(CO)3(κ3-L5)]+ (Re5) 
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The complex was prepared according to the methodology described in 2.5.1 
Briefly, L5 (18 mg, 0.12 mmol) reacted with the organometallic precursor 
[Re(CO)3(H2O)3]Br (50 mg, 0.12 mmol) in MeOH reflux for 3 h. After evaporation of the 
solvent the resulting residue was purified by preparative RP-HPLC (Method 2, section 
2.2.2). After that, the complex Re5 was isolated as a white solid.  
η = 75% 
 1H-NMR (300MHz, CD3OD; /ppm): 7.23 (s, 1H, CHe), 7.10 (s, 1H, CHf), 4.40 (d, J = 
1.5 Hz, 2H, CH2c), 3.76 (s, 3H, CH3d), 3.09 – 2.75 (m, 4H, CH4a,b) 
 13C-NMR (300MHz, CD3OD; /ppm): 153.88(Cg), , 129.36(Ce),  125.13 (Cf), 57.42 
(Cb), 51.52(Cc), 41.54(Ca), 34.97(Cd).    
 
 ESI-MS (+) (mass/charge-m/z): 425.2 [M+H]+, calculated for C10H14N4O3Re+ = 
424.45. 
 RP-HPLC (Method 2): Rt = 18.57 min  
 
2.6. SYNTHESIS AND CHARACTERIZATION OF 99MTC-COMPLEXES  
2.6.1. fac‐[99mTc(H2O)3(CO)3]+ precursor  
OH2
H2O
H2O
Tc
CO
COOC
 
To prepare the precursor, the following reagents were weighted in a glass vial 
(of 10mL capacity) and purged with N2: sodium tartrate dihydrate (8.50 mg), sodium 
tetraborate decahydrate (2.85 mg), sodium carbonate (7.15 mg) and sodium 
boranocarbonate (4.50 mg). Then, Na[99mTcO4] was eluted from a 99Mo/99mTc 
generator  with a solution of 0.9% (w/v) NaCl. From that eluate, 3.0 mL (~ 8.5 mCi) 
were added to the reaction vial, which was incubated at 100 °C for 30 min. After 
cooling the vial to r.t., the solution was neutralized with 1 M HCl (140 – 160 μL) to 
decompose any residual boranocarbonate.  
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RP-HPLC (Method 2): Rt = 8.87 min 
 
2.6.2. 99mTc complex fac-[99mTc(CO)3(κ3-L5)]+ (Tc5) 
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In a capped nitrogen purged glass vial, 500 μL of a 10‐4 M solution of the ligand 
L5, were added to a solution of fac-[99mTc(CO)3(H2O)3]+ (500 μL, 1.80 mCi, pH 7). The 
vial was incubated at 100 °C for 30 min and the resulting complex was analyzed by RP-
HPLC (Method 2) using the same method of the rhenium surrogate.  
RP-HPLC (Method 2): Rt = 19.20 min  
 
2.6.3. 99mTc complex fac-[99mTc(CO)3(κ3-L4)]+ (Tc4) 
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In a capped nitrogen purged plastic vial, 40µL of L4 (1,65x10-4 M, dissolved in 
water)  were added to a solution of fac-[99mTc(CO)3(H2O)3]+  (360 μL; 2.60 mCi) at pH 7. 
The vial was incubated at 90 °C for 30 min and Tc4 was analyzed by RP-HPLC (Method 2) 
and in comparison with the corresponding Rhenium complex.  
RP-HPLC (Method 2): Rt = 24.07 min  
 
 
 
 
  
 
 
 
  
 
 
 
 
 
3. Results and 
Discussion
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3.1. Synthesis of Ligands and Bifuncional Chelators (BFC’s)  
 
As mentioned before, the main goal of this work was to contribute for the design of 
new target-specific radiopharmaceuticals useful for in vivo imaging of GRP receptors 
overexpressed in prostatic neoplasias. To achieve such goal, we have explored the 
radiolabelling of a bombesin analogue peptide (AR) with the fac-[99mTc(CO)3]+ moiety. The 
bifuncional chelators contain pyrazolyl- and imidazolyl coordination groups, and present 
N,N,N donor atom sets. Both types of chelators contain a pendant arm with a terminal 
CO2H group for conjugation to the AR peptide. In all the BFC’s, the free terminal primary 
amine is protected with a Boc protecting group (Boc, tert-butyloxycarbonyl), in order to 
avoid undesirable side-reaction, namely lactamization, that will hamper the conjugation of 
the AR peptide. As it is shown in figure 3.1, the two pyrazolyl-containing BFC’s present 
spacers of different length, between the carboxylic acid  group and the chelating backbone. 
In this way, we expected to assess the influence of the chelating unit and/or spacer on the 
biological profile of the final radiolabeled bioconjugates. 
 
N
N N NH-Boc
COOH
L1-Boc
NN
N
L3.3-Boc
NH-Boc
COOH
N
N N NH-Boc
L2-Boc
COOH
 
Figure 3.1 –Boc-protected pyrazolyl and imidazolyl bifuncional chelators. 
 
3.1.1. Pyrazolyl-Based BFC’s 
The synthesis of the pyrazolyl-based BFC (L1-Boc) containing a propylenic spacer 
between the chelating unit and the carboxylic acid group has been performed as 
previously reported (62,97), using a multistep synthesis as depicted in scheme 3.1. 
The characterization of L1-Boc by 1H and 13C NMR gave data consistent with those 
described in the literature for this compound. (63) 
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Scheme 3.1 - Synthesis of L1-Boc; TBAB= tetrabutylammonium bromide 
The new BFC L2-Boc, containing a methylenic linker between the chelating 
unit and the carboxylic acid, was synthesized in moderate yield (61%), using a similar 
procedure to the one involved in the synthesis of L1-Boc(scheme 3.2); briefly, after 
alkylation of the central secondary amine in the Boc-protected pyrazolyl precursor, 
with benzyl bromoacetate, the ester group was hydrolyzed with Pd/C in the presence 
of H2 (scheme 3.2).  
  
Scheme 3.2 - Synthesis of L2-Boc (strategy 1). 
 All the intermediates and the final BFC, L2-Boc, were fully characterized by 
the usual analytical techniques, namely NMR spectroscopy, electrospray ionization 
mass spectrometry (ESI–MS) and reverse phase High-Performance Liquid 
Chromatography (RP-HPLC). 
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Figure 3.2 - 1H-NMR spectrum of L2-Boc in CDCl3. (S= residual CHCl3) 
 As an example, the 1H-NMR spectrum of L2-Boc in CDCl3 is presented in 
Figure 3.2. The assignment of the peaks present in the 1H-NMR spectrum was made by 
comparison with the peaks observed for similar compounds and based on the relative 
areas and chemical shifts of the different peaks. It was found all the expected 
resonances, namely the typical resonances for the  H(3)  (Hc ; δ 6.15) H(4) (Hd ; δ 6.15) 
and H(5) (He ; δ 7.46) protons of azolyl ring and the typical singlet for the methyl 
protons of Boc group. 
We also succeeded to obtain L2-Boc in a global yield (20%) by reaction of  N-2-
bromoethyl-pyrazole with benzyl 2-(2-(tert-butoxycarbonylamino)ethylamino)acetate, as 
presented in scheme 3.3. This strategy involved two N-alkylation reactions followed by the 
the selective deprotection of the benzyl group. This strategy can be useful to obtain BFC’s 
containing carboxylic groups at the 3- and 5- positions of the azolyl ring, aiming at the 
modulation of the pharmacokinetics of the respective tricabonyl complexes. Preliminary 
studies have shown that the first strategy does not work for the synthesis of this type of 
compounds due to side lactamization reaction involving the carboxylic substituents from 
the azolyl rings (data not shown). 
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Scheme 3. 3 - Synthesis of L2-Boc (strategy 2). 
.  
3.1.2 Imidazolyl derivatives  
As state above, the imidazolyl BFC was synthesized in order to evaluate the 
influence of the chelating unit on the biological profile of the correspondent bioconjugates. 
Moreover, the imidazolyl ring is also easily functionalized with selected functional groups 
(e.g. carboxylic acid) to further modulated the pharmacokinetics of the correspondent 
99mTc complexes, in the same way as the congener pyrazolyl-based BFC’s. To accomplish 
this goal, we decided to synthesize a model imidazolyl-diamine chelator to evaluate its 
coordination capability towards fac-[M(CO)3]+ (M = Re, 99mTc), as this class of ligands was 
not studied yet with these metallic cores. These studies were expected to partially predict 
the stability of Re(I) and 99mTc(I)-bioconjugate stabilized by BFC’s designed based on this 
imidazoyl-diamine backbone.  
As shown in scheme 3.4, the new imidazoyl-diamine chelator L5 was 
synthetized in a relatively fast and simple way based on the reductive amination of 
the desired imidazole aldehyde with Boc-protected ethylenediamine. The final 
compound has been obtained with an overall yield of 64.7%.  
 
Scheme 3.4 - Synthesis of L5. 
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Figure 3.3 - 1H-NMR spectrum of L5 in CD3OD or D2O. (S= residual Water from CD3OD) 
 The 1H NMR spectrum of L5 (Fig. 3.3) shows all the expected protons of the 
molecule: i) two resonances,integrating for one proton each, due to the CH e and CHf 
protons of the imidazol ring, are present at low field; ii) a sharp peak integrating to 
three protons, corresponding to the methyl protons is observed at high field; iii) the 
methylenic protons Ha and Hb of the imidazoyl-diamine backbone appear as 
multiplets, also at high field (δ 2.61  and 2.55); iv) the remaining methylenic protons 
(Hc)emerge as a singlet, at lower field. The two protons from the amines (NH2h and 
NHi) are not observed due to the hydrogen–deuterium exchange reaction (also called H–
D or H/D exchange) in which the hydrogen atoms are replaced by a deuterium atom, from 
the deuterated solvent. (98) 
Based on the chelating backbone of L5, we have studied the possibility of 
synthesizing imizadoyl-containing BFC’s similar to L1-Boc and L2-Boc. We could not 
explore the same synthetic pathway as in the case of the pyrazolyl congeners, since 
the N-alkylation of the imidazolyl-diamine backbone would be accompanied by the 
quaternization of the tertiary nitrogen atom from the imidazolyl ring. (99) Therefore, 
we have devised alternative procedures for the synthesis of the imidazolyl-containing 
BFC’s. Such strategies lied on the reductive amination of 1-methyl-2-
imidazolecarboxaldehyde with 4-(2-tert-Butoxycarbonylamino-ethylamino)-butyric 
acid ethyl ester (c9), using sodium triacetoxyborohydride as the reducing agent  
(Scheme 3.3). Compound c9 has been prepared by mono-alkylation of the primary 
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amine of tert-butyl 2-aminoethylcarbamate (c4). c9 was obtained in very low yield, 
due to competition of lactamization reactions, between the formed secondary amine 
and the ester of the ethyl 4-bromobutyrate arm. The occurrence of such lactamization 
reactions have precluded the synthesis of the final BFC, 4-[(2-tert-Butoxycarbonylamino-
ethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-butyric acid ethyl ester (L3.2-Boc) 
(Scheme 3.5).  
 
Scheme 3.5 – Synthetic pathway to attain 3-phenylpropyl 2-((2-tert-butoxycarbonylamino)ethyl)(1-metyl-
1H-imidazol-2-yl)methyl)amino)acetate 
The difficulties found on the synthesis of L3.2-Boc were avoided by using a 
shorter methylenic linker. This allowed the synthesis of L4-Boc (Scheme 3.6), which 
is the imidazolyl-containing congener of the above described L2-Boc. To synthesize 
L4-Boc we have started with the mono-alkylation of the primary amine of c4 with 
benzyl bromoacetate. As described above, this reaction gave c6 that was transformed 
into c7 upon reductive amination of 1-methyl-2-imidazolaldehyde. Finally, removal of 
the protecting  benzyl group with Pd/C in the presence of H2 gave L3-Boc, which was 
obtained with  an overall yield of 20%.  
 
Scheme 3.6 - Synthesis of L3-Boc. 
H2N NHBoc
ACN, 48h reflux , N2, 
KI, K2CO3, 
C6H10BNaO6
c4 ACN, 48h reflux ,
N2, KI, K2CO3
HN
N
H
Boc
c9
O
O
L 3.2-Boc
NN
N
NHBoc
O
O
ACN, 75min, Et3N
H2N NHBoc
DCM, reflux , 
N2, C6H10BNaO6
10% Pd/C
MeOH, 7h , H2
L3.3-Boc
c4
c6
NH HN
O
O
Boc
c7
O
O
NN
N
NHBoc
COOH
NN
N
NHBoc
L3-Boc 
  
 
  
59 
Organometalics Complexes of Tc(I) and Re(I) for  radiometalation of biological active  peptides Chapter 3 
   
 L3-Boc was fully characterized by the usual analytical techniques, namely 1H 
and 13C NMR spectroscopy, and electrospray ionization mass spectrometry (ESI–MS). 
The spectroscopic characterization corroborated the formulation proposed for L3-
Boc. As an example, the 13C NMR spectrum of this new BFC is presented in figure 3.4. In 
this spectrum are present all the expected resonanecs, namely the C=O of Carbon Ci and Cj 
at down  field (δ 176.85 and 156.42 ppm, respectively) 
  
Figure 3.4 - 1H-NMR spectrum of L3-Boc in CDCl3 (S= Residual CHCl3, from CDCl3) 
   
 
3.2. Synthesis, characterization and Biological evaluation of M(CO)3L5 
(M= Re, 99mTc) 
3.2.1. Synthesis and Characterization of the Re surrogate: 
Re(CO)3L5  
 As mentioned before, owing to the low concentration (10-8 – 10-10 M) of [99mTcO4]- 
in the saline solution extracted from the generator, it is impossible to characterize the 
resulting 99mTc complexes by the normal methods used in chemistry. Therefore, such 
complexes are often characterized by HPLC comparison with surrogate complexes 
syntehsized with the natural rhenium (“cold metal”), which present similar coordination 
chemistry.  
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  The imidazoyl derivative L5 was reacted with equimolar amount of the precursor 
fac-[Re(CO)3(H2O)]Br, in refluxing methanol during 3 h (scheme 3.7). This reaction yielded 
[Re(CO)3(κ3-L5)]+ (Re5), which was isolated in high yield after purification by preparative 
RP-HPLC. 
 
Scheme 3.7 - Synthesis of the complex Re5. 
Re5 was characterized by 1H, 13C and 2D-NMR spectroscopy, ESI-MS and RP-
HPLC. In the  ESI-MS spectrum we identified a peak with m/z=425.2 which the  
pattern of isotopic distribution is corresponding to the molecular peak [M+H]+  of the 
rhenium complex. As despicted in Figure 3.5, the tridentate coordination mode of the 
chelator was confirmed by the splliting pattern and chemical shifts of the several 
resonances 1H NMR.  The He,f and the methyl protons of the imidazoyl ring are shifted 
downfield (He,f,  ppm ; Hd ppm) relatively to the same resonances in L5. 
The methylenic protons of the coordinating backbone are also downfield shifted and,  
due to the  diastereotopic character of these methylenic protons after coordination to 
the metal center, they appears as multiplets.  The Hc protons emerges as a false singlet 
and the Ha,b protons as two multiplets, one  integrating for one proton and the other 
for three protons. This behavior, which is a strong evidence of ligand coordination, 
has been already observed in other tricarbonyl complexes of the same type previously 
described. (60,99–101) 
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Figure 3.5 - 1H-NMR spectrum (Top) and 13C-NMR spectrum (bottom) of Re5 in CD3OD. (S= solvent 
peak; S1= Residual Water from CD3OD; S2=Residual MeOH; S3= CD3OD) 
The 13C-NMR spectra showed all the resonances for the imidazoyl backbone 
and  two resonances for the CO ligands at downfield.  
  
Figure 3.6 –  ESI-MS spectrum of Re5. 
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The analysis of the 2D-experiment besides allowing the assignment of the 
peaks in the 1H spectra, give us information about the correlations between protons. 
In this case, we observe that the Hh and Hi are correlated with each other. Also, 
protons from the aromatic ring of Imz, He is correlated with Hd and Hc.  
 Analysing the ESI-MS spectra, presented in Figure 3.6, we identified a peak 
with m/z=425.1 that is  [M+H]+ with a teorical MW calculated for 424.45. And also, by 
the RP-HPLC chromatogram we found that 18.57 min was the characteristic retention 
time of Re 5. 
 
3.2.2. Synthesis and characterization of the  99mTc(CO3)L5 Complex 
To synthesis of fac-[99mTc(CO)3(κ3-L5)]+ (Tc5) was done by reacting L5 with 
the tricarbonyl precursor, [99mTc(CO3)(H2O)3]+ (103), which has been obtained by 
labeling the Isolink kit (IsoLink® kit, Mallinckrodt-Covidien, Petten, The Netherlands) 
with [99mTcO4]-, as described in detail in the experimental section. The formation of 
the precursor was controlled by RP-HPLC (figure 3.8), using method 2 (section 2.2.2). 
 
Figure 3.7 – RP-HPLC chromatogram of the tricarbonyl precursor. (Method 2)  
 
As shown in scheme 3.8, an aqueous solution of L5 (500 μL, [L5] = 10‐4 M) was 
reacted with the organometallic precursor fac-[99mTc(CO)3(H2O)3]+ (500 μL) at 100ᴼC for 
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30 min, affording fac-[99mTc(CO)3(κ3-L5)]+ (Tc5) in high yield and high radiochemical 
purity ( > 95 %). 
 
Scheme 3.8 – Synthesis of Tc5 
The formation of fac-[99mTc(CO)3(κ3-L5)]+ (Tc5) has been confirmed by HPLC 
comparison (Fig. 3.8) with the Re congener, fac-[Re(CO)3(κ3-L5)]+ (Re5), which has been 
fully characterized, as above discussed. The difference found in the retention times of the 
Re and 99mTc(I) complexes is due to the different paths involved in the detection of the 
complexes. The Re complex is detected with a UV-vis detector while the 99mTc complex is 
with a detector. These two detectors are connected in line.  
  
Figure 3.8 - RP-HPLC chromatograms of Tc5(γ - detection) and Re5 (UV detection). 
The characterization of fac-[99mTc(CO)3(κ3-L5)]+ (Tc5) involved also the 
assessment of its lipophilicity by measurement of the log Po/w value at pH = 7.4. Tc5 has a 
slightly lipophilic character (log Po/w = + 0.153 ± 0.06), contrarily to the analogous 99mTc 
pyrazolyl-diamine complex that is hydrophilic (log Po/w  =-0.93± 0.01) (63).  
3.2.3 BIODISTRIBUTION STUDIES 
The biological behavior of Tc5 was studied in CD-1 mice, to evaluate its 
biodistribution, pharmacokinetics and in vivo stability. Animals were intravenously 
injected in the tail. The biodistribution was evaluated at 1 h and 4 h post injection (p.i.). In 
particular, we were interested in the evaluation of blood clearance, route of 
elimination and eventual retention in some organs. In fact, the ideal 
100ºC, 30 min., pH 7
L 3.1
N
HN
N
NH2
OH2
H2O
H2O
Tc
CO
COOC
NH2
N
Tc3.1
H
Tc
CO
COOC
99mN
N
Re5  
18,57 
 
Tc5  
19,20 
 
L5 
Tc5 
  
64 
Organometalics Complexes of Tc(I) and Re(I) for  radiometalation of biological active  peptides Chapter 3 
radiopharmaceutical should be obtained in high yield and radiochemical purity and, 
after intravenous administration, should be rapidly excreted from non-target organs, 
preferably by the kidneys, avoiding the hepatobiliar pathway, which compromise 
their capacity to effectively image solid tumors and metastatic lesions in the 
abdomen. Moreover, the blood clearance must be fast enough to avoid long exposure 
to radiation, and slow enough to allow the radioactive compound to reach the target 
organ. 
Table 3.1 - Biodistribution studies of Tc5 at 1 h and 4 h p.i. (n = 3). 
Tissue/organ % AI/g ± SD 
 1 h 4 h 
Blood 0.22  0.03 0.07  0.01 
Liver 3.82  0,11 0.88  0.07 
 Intestine 9.03  1.53 6.22  2.48 
Spleen 0.22  0.00 0.15  0.01 
Heart 0.40  0.07 0.13  0.02 
Lung 0.37 0.20 0.18  0.03 
Kidney 2.59  0.04 1.03  0.27 
Muscle 0.10  0.01 0.05  0.01 
Bone 0.10  0.01 0.05  0.01 
Stomach 1.32  0.34 0.26  0.07 
 
  
Figure 3.9– Graphic representation of Tc5 Biosdistribution 
 Tc5 presented a favorable pharmacokinetic, it was rapidly cleared from the 
bloodstream (0.22  0.03 to 0.07  0.01 % IA/g, from 1h to 4h p.i.) and major organs, 
except those related to the excretion pathways. There is no significant uptake in the 
stomach, indicating a high stability of the complex to reoxidation. 
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3.2.4 IN VIVO STABILITY STUDIES 
 To study the in vivo stability of Tc5, urine and blood samples were collected from 
CD-1 mice injected with the radiotracer, at 1 h p.i. and 4h p.i.  After appropriate treatment, 
the biological samples were analyzed by RP‐HPLC. The blood was analyzed after 
precipitation of proteins, while urine was just centrifuged prior to the HPLC analysis. The 
chromatograms obtained are shown in figure 3.10 in comparison wih that of Tc5 (injected 
solution). The radiochromatograms showed no pertechnetate or other decomposition 
products, being Tc5 the only species present, demonstrating the high in vivo stability of 
the radiocomplex.  
 
Figure 3.10 - RP-HPLC  chromatograms of Tc5 (injected  preparation), blood serum and urine samples 
collected at 4 h p.i. (γ - detection/Method 2) 
 The favorable biological behavior of Tc5 indicated that chelators of the 
imidazolyl-diamine type have the necessary requirements to be used in the design of 
BFC’s for the labeling of peptides with fac-[99mTc(CO)3]+ and prompted us to proceed 
with its conjugation to BN antagonists. 
3.3. SYNTHESIS AND PURIFICATION OF BOMBESIN ANTAGONIST DERIVATIVES 
The  solid phase peptide synthesis methodology (SPPS) was first developed by 
Bruce Merrifield (Nobel Prize in Chemistry 1984) in the 1950s and 1960s, through the 
introduction of functionalized solid supports that enable amino acid coupling.(104) 
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The principle of SPPS is briefly illustrated in Figure 3.11. SPPS is based on the 
sequential addition (C→N direction) of Nα- and side-chain protected amino acids to a 
functionalized insoluble polymeric support, the resin. Typically, the C-terminal amino acid 
is first anchored by the carboxylate to the resin via a linker. Then, the Nα-protecting group 
can be removed without affecting the side-chain protecting groups and the peptide chain 
is prepared for the next coupling cycle. (105) The Nα-protecting groups most used in SPPS 
are the fluoren-9- ylmethyloxycarbonyl (Fmoc) and the tert-butoxycarbonyl (Boc), each a 
different and defining an overall strategy for SPPS. The Boc strategy, initially introduced 
by Merrifield, requires trifluoroacetic acid (TFA) or a similar acid for repetitive removal of 
the Boc groups, and hydrofluoric acid (HF) for peptide cleavage from the solid support, 
while the  Fmoc group can be removed under mild conditions with secondary amines, 
typically piperidine.(105) 
 
Figure 3.11 – Principle of peptide synthesis in Solid Phase. 
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In 2003, the first dedicated microwave-assisted peptide synthesizer was 
introduced (Liberty, CEM), which is a completely automated valve-based system. 
(106) The Microwave Technology /Chemistry have the fundamental mechanism of 
heating and involve the agitation of polar molecules or ions that oscillate under the 
effect of an oscillating electric or magnetic field. (Figure 3.12) 
 
 
Figure 3.12  - Electromagnetic effect of microwave in Peptide synthesis. 
The Microwave can overcome same disadvantages from the SPPS it allow 
faster reactions,  better yield and purity of peptide, better technology for difficult 
sequences,  heating efficiency, solvent less synthesis is possible, less solvent and 
reagents use with the importance of  greater reproducibility. However, Microwave 
strategy itself has problems as heating under elevated temperatures, the possibility of 
racemization of the Histidine and Cysteine, lack of scalability and the safety hazards 
associated with microwave. (107)  
We synthesized a bombesin-analogue peptide (Sta)based antagonist (AR) with 
an oligoethyleneglycol (PEG) spacer, in the N-terminal of the peptide. Briefly, the AR 
peptide sequence DPhe1-Gln2-Trp3-Ala4-Val5-Gly6-His7-Sta8-Leu9-NH2, shown in figure 
3.13, was assembled to the MBHA rink Amide resin by Fmoc-based Solid Phase Peptide 
Synthesis in a microwave-assisted peptide synthesizer, CEM 12-Channel Automated 
Peptide Synthesizer, using HOBT/HBTU/HATU as coupling agents, DMF as solvent and 
Dipea as base. In order to verify the main products formed in this synthesis, the 
peptide was cleaved from a small portion of the resin and, after appropriate work-up and 
purification by RP-HPLC, the peptide AR was characterized by ESI-MS (Figure 3.14). The 
peak found at m/z = 557.7 corresponds to [M+2H]2+ of the desired peptide and the peak 
found at m/z = 1130.4 could correspond to the species [M+NH3]+. It is also observed a 
peak at m/z = 976.9 with significant intensity, which correspondns to the peptide 
sequence without the His amino acid. This synthesis was repeated one more time and once 
again we observed the same reesult. This could indicate that the production of the AR 
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Peptide by SPPS is hampered by the use of microwave associated with the introduction of 
the His aminoacid.   
 
Figure 3.13 - Structural configuration of AR peptide after resin deprotection .  
 
Figure 3. 14 - ESI-MS spectrum of AR peptide. 
Recently the use of PEG’s with Bombensin antagonists derivatives was 
investigated. In a study made by James M. et al  it was studied the influence of PEG with 
different length, on the biological profile of the AR peptide conjugate with different 
chelators and radionuclides. (82). They conclude  that the PEG4 and PEG6 showed 
significantly better properties, then PEG12 . They present a  very high tumor-to-non-target 
organ ratios, in particular tumor-to-kidney ratios, that are important in regard to safety 
concerning kidney toxicity. However, shorter oligo-PEG derivatives have not been 
evaluated yet; the autors wonder if these small PEGs still maintain high binding affinity 
and concomitantly suitable pharmacokinetics (82).  
In order to answer this question and aiming to provide a more hydrophilic 
character to our bioconjugates, we decide to couple a small PEG to the previously 
described AR peptide. To the AR peptide, still attached to the resin and without any 
purification, was coupled with success a PEG2 linker, using the same methodologies 
involved in the synthesis of the peptide itself (Scheme 3.9).  
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Scheme 3.9 – Synthesis of ARPEG2 
As showed in scheme 3.9, this coupling was done manually by SPPS with a 
commercial Fmoc protected PEG2, using HATU as coupling agent, DMF as solvent and 
Dipea as base. After two cycles of coupling we could verify by Kaiser Test  that all 
amine bonds were consumed. For characterization purposes, only a small part of the 
resin was deprotected. As showed in Figure 3.15, the ESI-MS analysis revealed a peak 
at m/z = 1258.9 corresponding to [M+H]+ of the desired peptide conjugate (ARPEG2) and a 
more intense peak at m/z = 1123.1 corresponding to [M+H]+ of the PEG2 conjugate 
without the His amino acid, in agreement with the ESI-MS results obtained in the synthesis 
of the AR peptide. 
 
Figure 3.15 - ESI-MS spectrum of ARPEG2 peptide. 
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3.4. CONJUGATION OF THE BOMBESIN ANTAGONIST TO THE BFC’S  
L1-Boc was conjugated to ARPEG2, via HATU activation in the presence of 
DIPEA in a DMF solution and with microwave irradiation (Scheme 3.10). 
 
Scheme 3.10 - Synthesis of L4, the conjugate of ARPEG2 with L1-Boc. 
 After removal of the protecting groups, with a standard deprotection cocktail, 
appropriate work-up and purification by RP-HPLC, the final conjugate was characterized 
by ESI-MS. The peak found at m/z = 1481.5 have the isotopic pattern corresponding  to the 
[M+H]+ of the desired bioconjugate. The ESI-MS spectrum and the RP-HPLC chromatogram 
of L4 peptide conjugate are shown in figures 3.16 and 3.17, respectively 
 
Figure 3.16 - Structural configuration of L4 peptide conjugate after resin deprotection. 
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Figure 3.17 - ESI-MS spectrum of L4 peptide conjugate. 
 
 
Figure 3.18 – HPLC chromatogram of L4 peptide conjugate. (Method 1, section 2.2.2) 
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It has been attempted the conjugation of ARPEG2 with the pyrazolyl and 
imidazolyl-based BFC’s having a shorter linker, L2-Boc and L3-Boc, respectively, 
based on the methodology that has been used to obtain L4: i.e. conjugation reaction 
via HATU activation in the presence of DIPEA in a DMF solution and with microwave 
irradiation (Scheme 3.11). After resin deprotection, the resulting mixtures were 
analyzed by ESI-MS before purification.  
 
Scheme 3.11 – Attempts to synthesize L6 and L7 by conjugation of ARPEG2 with the desired BFC. 
 
In the case of the synthesis of L6, the ESI-MS results were ambiguous. The 
spectrum did not reveal the presence of the m/z peak of the desired peptide 
conjugate, while the peak found at m/z= 1298.5 [M+ACN]+ certainly corresponds to 
ARPEG2. For L7, the results from the ESI-MS spectrum also did not reveal the 
presence of a m/z peak of the desired peptide conjugate. So, the conjugation reactions 
to obtain L6 and L7 need to be performed with other experimental conditions in 
order to obtain the desired products. 
 
3.5. Synthesis and Characterization of Metalated Peptides: fac-
[M(CO)3(L4)]+ (M=Re, 99mTc)  
 
As previously stated, to characterize the 99mTc(CO)3-complexes is necessary to 
synthesize the  natural  “cold” rhenium complexes, which present similar physico-chemical 
properties. Moreover, in the case of metalated peptides the cold Re complexes are useful 
to determine the in vitro binding affinity towards the respective receptors. The 
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metalopeptide with L4, Re4, was synthesized via a direct method as displayed in Scheme 
3.12. 
 
Scheme 3.12 - Synthesis of the metallated peptide Re4. 
The peptide conjugate L4 reacted with equimolar amounts of the precursor 
fac-[Re(CO)3(H2O)3]Br, in refluxing MeOH during 72 h. After purification by 
preparative RP-HPLC (Method 2, section 2.2.2), the Re4 complex of the peptide 
conjugate L4 was characterized by ESI-MS and RP-HPLC. The analysis of the ESI-MS 
revealed a peak at m/z = 1751  corresponding to [M+H]+. The peak found in  RP-HPLC 
(method 2) had a retention time of 23.17 min. 
Peptide conjugate L4 was labeled with 99mTc(I), following the methodology above 
described for the labeling of L5. As is shown in Scheme 3.12, reaction of the peptide 
analogue L4 (40 μL, [L4] = 1,65 x 10-4 M) with the organometallic precursor fac-
[99mTc(CO)3(H2O)3]+ (360 μL), after 45 min at 90:C, gave the desired radiometalated 
peptide fac-[99mTc(CO)3(κ3-L4)]+ (Tc4) (tR = 24.07 min) in a reduced yield and 
contaminated with a major unidentified  radiochemical impurity  (figure 3.19).  
 
Scheme 3.13 – Synthesis of Tc4. 
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Figure 3.19 – RP-HPLC chromatograms of Tc4(γ - detection)/Re4 (U.V. detection). 
 
We tried to radiolabel the conjugate peptide L4 using other experimental 
conditions, namely higher concentration of L4 and higher temperature, longer 
reaction time, different pH. We also tried to dissolve L4 in ethanol to avoid its 
eventual precipitation during the labeling reaction, since L4 has poor solubility in 
aqueous solution. To improve the dissolution of L4, with a consequent higher 
concentration of the peptide conjugate in solution, we have used a solution of acetic 
acid in water (10:90).  However, under all the tested conditions, it was not possible to 
improve the yield and purity of this radioconjugate. In summary, further work is 
necessary to improve the radiolabeling yield and to perform the subsequent in 
vitro/in vivo studies with this radioconjugate. 
 
Re4  
Tc4  
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The main goal of this thesis was contribute for the development of 
radiopharmaceuticals based on [99mTc(CO)3]+ for the in vivo imaging of tumors 
overexpressing the Gastrin Releasing peptide-receptor (GRP-r,), particularly prostate 
cancer.  
To accomplish this main goal, three different BFC’s containing pyrazolyl (L1, L2) 
and imidazolyl (L3) coordinating groups were synthesized, characterized and conjugated 
to a bombesin antagonist (AR) peptide, with known ability to target GRP-r. In general, all 
the BFC’s were obtained with high purity and reasonable yields. The investigated BFC's 
contain N,N,N donor atom sets in order to be applied within the tricarbonyl approach. 
Both types of chelators have a pendant arm with a terminal carboxylate group for 
conjugation to the AR peptide.  
The coordination behaviour of imidazolyl-diamine ligands, corresponding to the 
chelating backbone of L3, towards the fac-[M(CO)3]+ (M = Re, 99mTc) core was not studied 
yet. Therefore, it has been synthesized a model ligand (L5) without pendant carboxylate 
group, which allowed the synthesis of the organometallic complexes fac-[M(CO)3(κ3-L5)]+ 
(M = Re (Re5), 99mTc (Tc5)). Tc5 presented a favorable biological profile and a high, 
stability in vivo, which showed that imidazolyl-diamine ligands have the necessary 
requisites to be used in the desugn of BFC’s for labeling of peptides with fac-[M(CO)3]+.  
 Peptide synthesis and its PEGylation were successfully accomplished, although a 
significant amount of conjugates without the histidine residue were obtained. This point 
need to be improved by changing the coupling conditions. Nevertheless, the non-purified 
conjugate ARPEG2 was functionalized with the pyrazolyl-containing BFC having the larger 
linker, affording L4 that was obtained with high purity after RP-HPLC purification.  
However, the efficient conjugation of the peptide to the BFC required microwave 
technology. In our hands, such technology did not allow the coupling of ARPEG2 to the 
pyrazolyl- and imidazolyl-containing BFC’s having a shorter linker between the ligand 
backbone and the pendant carboxylic group.  
 The new peptide conjugate L4 was radiolabeled with fac-[99mTc(CO)3]+ but the 
resulting radiometalated peptide, identified by HPLC comparison with the Re congener, 
was obtained with low yield and unsatisfactory radiochemical purity. More studies are 
foreseen to optimize the radiolabeling of L4.  
The tricarbonyl approach allows the use of the matched pair Tc(I)/Re(I), taking 
advantage of the therapeutic applications of Re radionuclides. This might open the way for 
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the development of a theranostic radiolabeled peptide, having at the same time imaging 
and therapeutic properties. To achieve this goal it is necessary to improve the 
pharmacokinetic of the conjugates in order to have high ratio between target and non-
target organs. It is known that 99mTc/188Re-tricarbonyl-based radiometalated peptides can 
be lipophilic, and structural modification are necessary to improve their biological profile. 
As proposed in this work such modification can comprise the use of PEG moieties and/or 
the modification of the BFC’s. Unfortunately, we weren’t able to finish all the proposed 
studies, and evaluate the effect of different structural alterations on the binding affinity, 
cellular uptake, tumor uptake and target/non-target ratio of the final radiopeptides.  
In future studies is essential to continue with the purification and radiolabelling of 
L6 and L7. More importantly, the radiolabelling yield of L4 must be improved. In this way, 
the biological evaluation of the different compounds can be accomplished, which is 
expected to show if the devised strategy is adequate to improve the performance of 
M(CO)3-labeled bombesin antagonists as theranostic tools for the management of GRR-r 
positive tumors, particularly prostate cancer. 
Concerning the Budget (See annex), the work involved in this Thesis it’s a 
expensive labor. Nevertheless, to conclude, we can definitely consider that the majority of 
the described processes can be improved towards the use of less solvents and reagents, 
with consequent lower investment. 
.  
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5. Appendix 
Budjet 
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Products 
Molecular 
Formula 
Manufacturer Cas-number 
Quantity for 
unit 
  
Price per 
unit /€ 
Amount 
used 
  Price/€ 
Diclomethane(DCM) CH2Cl2 Sigma-Aldrich 75-09-2 1,00 L 
25,90 
2,00 L 51,80 
chloroform CHCl3 scharlau 67-66-3 2,50 L 
72,50 
2,50 L 72,50 
Petroleum ether C7H7BrMg Sigma-Aldrich 8032-32-4 2,50 L 85,00 0,05 L 1,70 
Ethyl Acetate(EtOAc) CH3COOC2H5 Carlo-Erba 141-78-6 2,50 L 81,80 0,02 L 0,65 
Acetone (CH3)COCH3 Carlo-Erba 67-64-1 45,00 L 1120,00 0,01 L 0,25 
n-hexane CH3(CH2)4CH3 Sigma-Aldrich 110-54-3 2,50 L 81,20 0,50 L 16,24 
Tetrahydrofurane 
(THF) 
C4H8O Carlo-Erba 109-99-9 2,50 L 74,40 0,10 L 2,98 
Ethanol (EtOH)  CH3CH2OH Panreac 64-17-5   1,00 L 121,35 0,03 L 3,64 
Methanol (MeOH)  CH3OH Carlo-Erba 67-56-1 5,00 L 84,60 0,50 L 8,46 
Diethylether (CH3CH2)2O Sigma-Aldrich 60-29-7 2,50 L 67,10 0,01 L 0,27 
Acetonitrile (ACN) CH3CN  Sigma-Aldrich 75-05-8 2,50 L 157,50 2,50 L 157,50 
N,N-
Dimethylformamide 
(DMF)  
HCON(CH3)2 Carlo-Erba 68-12-2 2,50 L 124,00 2,50 L 124,00 
Trifluoroacetic acid 
(TFA) 
CF3COOH Sigma-Aldrich 76-05-1 100,00 mL 128,50 50,00 mL 64,25 
Water H2O In house . . . . . . 0,00 
N,N-
Diisopropylethylamin
e (Dipea) 
[(CH3)2CH]2NC2
H5 
Sigma-Aldrich 7087-68-5 500,00 mL 132,50 25,00 mL 6,63 
Piperidine C5H11N Sigma-Aldrich 110-89-4 500,00 mL 60,10 15,00 mL 1,80 
1,4-Dioxane C4H8O2 Sigma-Aldrich 123-91-1 2,50 L 197,00 0,18 L 14,18 
Triethylamine (C2H5)3N Sigma-Aldrich 121-44-8 100,00 mL 21,60 1,51 mL 0,33 
D
eu
te
ra
te
d
 
S
o
lv
en
ts
 Deuterochloroform CDCl3 Sigma-Aldrich 865-49-6 5,00 mL 38,80 10,00 mL 77,60 
Tetradeuteromethan
ol 
CD3OD Euriso-top 811-98-3 5,00 mL 159,50 3,00 mL 95,70 
  
Total costs of Solvents = 700,48 € 
R
ea
g
en
ts
 
Benzyl Bromoacetate C9H9BrO2 Sigma-Aldrich 5437-45-6 50,00 g 21,80 1,28 g 0,56 
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Di-tert-butyl 
dicarbonate (Boc 
protective group) 
[(CH3)3COCO]2O Sigma-Aldrich 24424-99-5 25,00 g 85,70 14,00 g 47,99 
1,2-dibromoethane  BrCH2CH2Br Sigma-Aldrich 106-93-4 200,00 mL 46,20 95,00 mL 21,95 
Ethyl 4-
bromobutyrate 
C6H11BrO2 Sigma-Aldrich 2969-81-5 50,00 g 32,60 1,40 g 0,91 
Ethylenediamine NH2CH2CH2NH2 Sigma-Aldrich 107-15-3 500,00 mL 25,60 27,00 mL 1,38 
Hydrochloric acid HCl Sigma-Aldrich 7647-01-0 2,50 L 133,50 0,007 L 0,37 
Magnesium sulfate 
anhydrous 96% 
MgSO4  Panreac 7487-88-9 500,00 g 81,20 5,00 g 0,81 
1-Methyl-2-
imidazolecarboxalde
hyde 
C5H6N2O  Sigma-Aldrich 13750-81-7 5,00 g 136,00 0,42 g 11,42 
Pyrazol  C3H4N2 Sigma-Aldrich 288-13-1 25,00 g 45,20 10,50 g 18,98 
Palladium on Carbon 
(Pd/C) 
Pd Sigma-Aldrich 
MFCD034578
79 
10,00 g 156,50 1,00 g 15,65 
Potassium Iodide KI Sigma-Aldrich 7681-11-0 100,00 g 33,60 0,03 g 0,01 
Potassium 
Carbonate 
K2CO3 Sigma-Aldrich 584-08-7 25,00 g 122,00 3,10 g 15,13 
Sodium Hidroxide NaOH Sigma-Aldrich 1310-73-2 500,00 g 38,50 16,50 g 1,27 
sodium 
triacetoxyborohydrid
e  
(CH3COO)3BHN
a 
Sigma-Aldrich 56553-60-7 25,00 g 61,00 0,22 g 0,54 
Sodium borohydride NaBH4 Sigma-Aldrich 16940-66-2 25,00 g 43,00 0,35 g 0,60 
Tetrabutylammonium 
bromide (TBAB) 
(CH3CH2CH2CH2
)4N(Br) 
Sigma-Aldrich 1643-19-2 25,00 g 25,80 1,20 g 1,24 
Total costs of Reagents = 138,82 € 
 P
ep
ti
d
e 
S
yn
th
es
is
 
HATU C10H15F6N6OP Sigma-Aldrich 148893-10-1   25,00 g 414,50 0,42 g 7,01 
FMOC-Ala-OH C18H17NO4  Novabiochem 35661-39-3 5,00 g 50,00 0,37 g 3,72 
Budjet 
 
 
FMOC-D-
Phenylanine-OH 
C24H21NO4 Novabiochem 86123-10-6 5,00 g 50,00 0,46 g 4,63 
FMOC-Gln(Trt)-OH C39H34N2O5 Sigma-Aldrich 132327-80-1 5,00 g 41,80 1,99 g 16,64 
FMOC-Gly-OH C17H15NO4 Novabiochem 29022-11-5 5,00 g 11,00 1,99 g 4,38 
FMOC-His(Trt)-OH C10H15NO4 Sigma-Aldrich 109425-51-6   5,00 g 41,80 0,37 g 3,09 
FMOC-His(Trt)-OH C40H33N3O4 Novabiochem 109425-51-6 5,00 g 35,00 1,36 g 9,55 
FMOC-Leu-OH C27H23NO4 Novabiochem 35661-60-0 5,00 g 11,00 0,43 g 0,95 
FMOC-NH-PEG-
COOH (9 atoms) 
C21H23NO6 Novabiochem 166108-71 1,00 g 300,00 0,40 g 119,70 
FMOC-Trp(Boc)-OH C31H30N2O6 Sigma-Aldrich 143824-78-6   5,00 g 50,00 2,28 g 2,28 
FMOC-Sta-OH C23H27NO5 Novabiochem 158257-40-0 25,00 mg 44,30 460,00 mg 815,12 
FMOC-Val-OH C20H21NO4 Novabiochem 68858-20-8 5,00 g 11,00 1,54 g 3,39 
Rink Amide-MBHA Resin Novabiochem 431041-83-7 5,00 g 212,00 0,97 g 40,92 
  
Total cost of peptide synthesis= 1.031,36 € 
M
at
er
ia
ls
 
silica 230-400 mesh SiO₂ Merck 7631-86-9 
5,00 kg 425,50 2,00 kg 170,20 
TLC Silica gel 60 
F₂₅₄ 
. Merck . 
25,00 
un/b
ox 63,76 € 10,00 un 25,50 
pasteur pipets . Normax . 250,00 
un/b
ox 5,46 € 350,00 un 7,64 
Filter Paper . Sigma-Aldrich Whatman Article 
No. 28413929 1,00 
un/b
ox 27,90 € 2,00 un 55,80 
Aluminium Foil . Supermarkets 
. 1,00 
un/b
ox 1,27 € 1,00 un 1,27 
glass Material (new 
and repairs) . . . . . . . . 150,80 
Parafilm . Parafilm . 0,04 m 566,00 0,004 m 59,58 
Total costs of Laboratory Material = 470,80 € 
  
                  
Estimated 
price/€ 
O
th
er
 c
o
st
s Nitrogen gas (N2) used to dry solvents and do reaction under N2 atmosphere (considering 10 months) 400,00 € 
Water  used in reactions with reflux (considering 10 months) 200,00 € 
electricity used in all the electric equiment, namely Microwave (considering 10 months) 200,00 € 
  
TOTAL = 3.141,46 €   
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